AEye (LIDR) 10-K15 Mar 232022 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2022	Mar. 10, 2023	Jun. 30, 2022
Entity Listings [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	333-259554
Entity Registrant Name	AEye, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	37-1827430
Entity Address, Address Line One	One Park Place
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Dublin
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94568
City Area Code	(925)
Local Phone Number	400-4366
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 205,000,000
Entity Common Stock, Shares Outstanding		168,762,257
Documents Incorporated by Reference	Portions of the Registrant’s Proxy Statement relating to the 2023 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement, or an amendment to this Annual Report on Form 10-K, will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2022.
Amendment Flag	false
Entity Central Index Key	0001818644
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Common Stock
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	LIDR
Security Exchange Name	NASDAQ
Warrants
Entity Listings [Line Items]
Title of 12(b) Security	Warrants to purchase one share of common stock
Trading Symbol	LIDRW
Security Exchange Name	NASDAQ

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	34
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Location	San Francisco, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 19,064	$ 14,183
Marketable securities	75,135	149,824
Accounts receivable, net	617	4,222
Inventories, net	4,553	4,085
Prepaid and other current assets	6,181	5,051
Total current assets	105,550	177,365
Right-of-use assets	15,502	0
Property and equipment, net	7,665	5,129
Restricted cash	2,150	2,150
Other noncurrent assets	2,473	1,509
Total assets	133,340	186,153
CURRENT LIABILITIES:
Accounts payable	3,218	2,542
Accrued expenses and other current liabilities	9,764	8,739
Contract liabilities	987	2,287
Convertible notes	8,594	0
Total current liabilities	22,563	13,568
Operating lease liabilities, noncurrent	16,681	0
Deferred rent, noncurrent	0	3,032
Other noncurrent liabilities	126	786
Total liabilities	39,370	17,386
COMMITMENTS AND CONTINGENCIES (Note 21)
STOCKHOLDERS’ EQUITY:
Preferred stock—$0.0001 par value: 1,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock—$0.0001 par value: 300,000,000 shares authorized; 163,099,124 and 155,137,237 shares issued and outstanding at December 31, 2022 and 2021	16	16
Additional paid-in capital	345,742	320,937
Accumulated other comprehensive loss	(1,279)	(391)
Accumulated deficit	(250,509)	(151,795)
Total stockholders’ equity	93,970	168,767
Total liabilities and stockholders’ equity	$ 133,340	$ 186,153

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock — par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock — shares authorized (in shares)	1,000,000	1,000,000
Preferred stock — shares issued (in shares)	0	0
Preferred stock — shares outstanding (in shares)	0	0
Common stock — par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock — shares authorized (in shares)	300,000,000	300,000,000
Common stock — shares issued (in shares)	163,099,124	155,137,237
Common stock — shares outstanding (in shares)	163,099,124	155,137,237

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
REVENUE:
Total revenue	$ 3,647	$ 3,007
Cost of revenue	8,732	3,637
Gross loss	(5,085)	(630)
OPERATING EXPENSES:
Research and development	37,644	26,543
Sales and marketing	19,317	10,548
General and administrative	36,762	25,514
Total operating expenses	93,723	62,605
LOSS FROM OPERATIONS	(98,808)	(63,235)
OTHER INCOME (EXPENSE):
Change in fair value of convertible note, embedded derivative liability, and warrant liabilities	(14)	223
Gain on PPP loan forgiveness	0	2,297
Interest income and other	1,545	561
Interest expense and other	(1,379)	(4,857)
Total other income (expense), net	152	(1,776)
Provision for income tax expense	58	0
Net loss	(98,714)	(65,011)
Change in net unrealized loss on available-for-sale securities, net of tax	(940)	(391)
Change in fair value due to instrument-specific credit risk, net of tax	(25)	0
Net losses reclassified into income during the period, net of tax	77	0
Comprehensive loss	$ (99,602)	$ (65,402)
PER SHARE DATA
Net loss per common share (basic) (in dollars per share)	$ (0.63)	$ (0.60)
Net loss per common share (diluted) (in dollars per share)	$ (0.63)	$ (0.60)
Weighted average common shares outstanding (basic) (in shares)	157,368,707	109,055,894
Weighted average common shares outstanding (diluted) (in shares)	157,368,707	109,055,894
Prototype sales
REVENUE:
Total revenue	$ 1,743	$ 1,004
Development contracts
REVENUE:
Total revenue	$ 1,904	$ 2,003

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Previously reported	Retroactive application of recapitalization	Preferred Stock	Preferred Stock Previously reported	Preferred Stock Retroactive application of recapitalization	Common Stock	Common Stock Previously reported	Common Stock Retroactive application of recapitalization	Additional Paid-in Capital	Additional Paid-in Capital Previously reported	Additional Paid-in Capital Retroactive application of recapitalization	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Previously reported	Accumulated Other Comprehensive Loss Retroactive application of recapitalization	Accumulated Deficit	Accumulated Deficit Previously reported	Accumulated Deficit Retroactive application of recapitalization
Beginning balance (in shares) at Dec. 31, 2020				0	16,383,725	(16,383,725)
Beginning balance (in shares) at Dec. 31, 2020							101,286,645	10,838,010	90,448,635
Beginning balance at Dec. 31, 2020	$ (18,225)	$ (18,225)	$ 0	$ 0	$ 62,639	$ (62,639)	$ 10	$ 0	$ 10	$ 68,549	$ 5,920	$ 62,629	$ 0	$ 0	$ 0	$ (86,784)	$ (86,784)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)							204,119
Net settlement of common stock and Series A preferred stock warrants (in shares)							240,806
Conversions of convertible note into common stock (in shares)							20,778,097
Ending balance (in shares) at Aug. 15, 2021	16,383,725
Beginning balance (in shares) at Dec. 31, 2020				0	16,383,725	(16,383,725)
Beginning balance (in shares) at Dec. 31, 2020							101,286,645	10,838,010	90,448,635
Beginning balance at Dec. 31, 2020	$ (18,225)	$ (18,225)	$ 0	$ 0	$ 62,639	$ (62,639)	$ 10	$ 0	$ 10	68,549	$ 5,920	$ 62,629	0	$ 0	$ 0	(86,784)	$ (86,784)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	10,018									10,018
Issuance of common stock upon exercise of stock options (in shares)							312,037
Issuance of common stock upon exercise of stock options	150									150
Business combination and PIPE financing (in shares)							31,894,635
Business combination and PIPE financing	256,811						$ 3			256,808
Transaction costs related to Business Combination and PIPE financing	(52,661)									(52,661)
Net settlement of common stock and Series A preferred stock warrants (in shares)							240,806
Assumption of the private placement warrant liability in connection with Business Combination	(268)									(268)
Commitment shares for Common Stock Purchase Agreement (in shares)							302,634
Issuance of common stock under the Common Stock Purchase Agreement	1,583									1,583
Repurchase of stock options	(1,500)									(1,500)
Issuance of common stock upon vesting of restricted stock units (in shares)							448,604
Issuance of common stock upon vesting of restricted stock units	1						$ 1
Taxes related to net share settlement of equity awards (in shares)							(126,221)
Taxes related to net share settlement of equity awards	(835)									(835)
Conversions of convertible note into common stock (in shares)							20,778,097
Conversions of convertible note into common stock	39,095						$ 2			39,093
Other comprehensive loss, net of tax	(391)
Unrealized loss on available-for-sale debt securities	(391)												(391)
Net loss	$ (65,011)															(65,011)
Ending balance (in shares) at Dec. 31, 2021	0			0
Ending balance (in shares) at Dec. 31, 2021	155,137,237						155,137,237
Ending balance at Dec. 31, 2021	$ 168,767			$ 0			$ 16			320,937			(391)			(151,795)
Beginning balance (in shares) at Aug. 15, 2021	16,383,725
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversions of convertible note into common stock (in shares)							20,778,097
Ending balance (in shares) at Aug. 16, 2021	154,404,302
Beginning balance (in shares) at Dec. 31, 2021	0			0
Beginning balance (in shares) at Dec. 31, 2021	155,137,237						155,137,237
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 23,959									23,959
Issuance of common stock upon exercise of stock options (in shares)	3,219,957						3,219,957
Issuance of common stock upon exercise of stock options	$ 1,174									1,174
Commitment shares for Common Stock Purchase Agreement (in shares)							1,145,000
Issuance of common stock under the Common Stock Purchase Agreement	2,891									2,891
Issuance of common stock upon vesting of restricted stock units (in shares)							3,908,031
Taxes related to net share settlement of equity awards (in shares)							(1,340,810)
Taxes related to net share settlement of equity awards	(3,790)									(3,790)
Transaction costs related to the Common Stock Purchase Agreement	$ (29)									(29)
Issuance of common stock upon exercise of public warrants (in shares)							10
Conversions of convertible note into common stock (in shares)	1,029,699
Conversions of convertible note into common stock	$ 600
Other comprehensive loss, net of tax	(888)												(888)
Unrealized loss on available-for-sale debt securities	(940)
Net loss	$ (98,714)															(98,714)
Ending balance (in shares) at Dec. 31, 2022	0			0
Ending balance (in shares) at Dec. 31, 2022	163,099,124						163,099,124
Ending balance at Dec. 31, 2022	$ 93,970			$ 0			$ 16			$ 345,742			$ (1,279)			$ (250,509)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (98,714)	$ (65,011)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,422	1,014
Noncash lease expense relating to operating lease right-of-use assets	1,338	0
Noncash common stock purchase agreement costs	0	1,583
Inventory write-downs, net of scrapped inventory	675	1,203
Change in fair value of convertible note, embedded derivative liability, and warrant liabilities	14	(223)
Noncash gain on PPP loan forgiveness	0	(2,297)
Stock-based compensation	23,959	10,018
Convertible note issuance costs	474	0
Amortization of debt issuance costs	0	725
Amortization of debt discount	0	752
Realized loss on redemption of marketable securities	77	0
Amortization of premiums on marketable securities, net of change in accrued interest	1,086	310
Other	0	287
Changes in operating assets and liabilities:
Accounts receivable, net	3,605	(4,066)
Inventories, current and noncurrent, net	(2,634)	(2,633)
Prepaid and other current assets	(1,130)	(3,655)
Other noncurrent assets	527	(1,483)
Accounts payable	839	557
Accrued expenses and other current liabilities	85	5,496
Operating lease liabilities	(1,341)	0
Deferred rent	0	(538)
Contract liabilities	(1,931)	2,258
Net cash used in operating activities	(71,649)	(55,703)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,200)	(1,021)
Proceeds from redemptions and maturities of marketable securities	96,592	0
Purchase of available-for-sale securities	(23,929)	(150,525)
Net cash provided by (used in) investing activities	68,463	(151,546)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	1,174	150
Proceeds from Business Combination and PIPE financing	0	256,811
Transaction costs related to Business Combination and PIPE financing	0	(52,372)
Proceeds from the issuance of convertible notes	9,850	8,045
Payments for convertible note redemptions	(874)	0
Payment of 2022 convertible note issuance costs	(324)	0
Proceeds from bank loan	0	10,000
Principal payments on bank loans	0	(13,333)
Payment of debt issuance costs	0	(717)
Taxes paid related to the net share settlement of equity awards	(4,621)	0
Repurchase of stock options	0	(1,500)
Proceeds from issuance of common stock under the Common Stock Purchase Agreement	2,891	0
Payment of transaction costs related to the Common Stock Purchase Agreement	(29)	0
Net cash provided by financing activities	8,067	207,084
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	4,881	(165)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period	16,333	16,498
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Ending	21,214	16,333
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	133	358
Cash paid for income taxes	20	0
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Purchases of property and equipment included in accounts payable and accrued liabilities	28	270
Operating lease right-of-use assets obtained in exchange for lease obligations	556	0
Conversion of Series A and Series B preferred stock into Class A common stock	0	62,639
Conversion of convertible notes and accrued interest into Class A common stock	600	39,095
Taxes related to net share settlement of equity awards included in accrued liabilities	4	835
Assumption of the private placement warrant liability in connection with Business Combination	0	268
Transaction costs paid in 2020, previously recorded to other non-current assets and reclassified to additional paid-in capital in 2021	0	289
Cumulative Effect, Period of Adoption, Adjustment
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Operating lease right-of-use assets obtained in exchange for lease obligations	$ 16,284	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
Organization and Summary of Significant Accounting Policies	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AEye, Inc. (the “Company” or “AEye”) is a provider of high-performance, active lidar systems for vehicle autonomy, advanced driver-assistance systems (ADAS), and robotic vision applications. AEye’s software-definable 4Sight TM Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. On February 17, 2021, AEye Technologies, Inc., then known as AEye, Inc. (“AEye Technologies”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with CF Finance Acquisition Corp. III, a Delaware corporation (“CF III”), now known as AEye, Inc., and Meliora Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of CF III (“Merger Sub”). Based on CF III’s business activities, it was a “shell company” as defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). On August 16, 2021 (the “Closing Date”), CF III closed the business combination (the “Business Combination,” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”) pursuant to the Merger Agreement, and Merger Sub was merged with and into AEye Technologies with AEye Technologies surviving the merger as a wholly owned subsidiary of CF III. On the Closing Date, and in connection with the closing of the Transactions (the “Closing”), CF III changed its name to AEye, Inc. The Company’s common stock and public warrants are now listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbols “LIDR” and “LIDRW”, respectively. Unless otherwise specified, “we,” “us,” “our,” “AEye,” and the “Company” refers to AEye, Inc., the combined entity following the Business Combination. Refer to Note 2 for further discussion of the Business Combination. Principle of Consolidation and Liquidity The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has funded its operations primarily through the Business Combination and issuances of stock. As of December 31, 2022, the Company’s existing sources of liquidity included cash, cash equivalents and marketable securities of $94.2 million. The Company has incurred losses and negative cash flows from operations. As the Company incurs additional losses in the future, it may need to raise additional capital through issuances of equity and debt. However, management believes that the Company’s existing sources of liquidity are adequate to fund its operations for at least the next 12 months. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. Advances to suppliers has been broken out from Other within Footnote 6, Prepaid and other current assets. Amortization of premiums on marketable securities, net within Footnote 13, Interest Expense and Other is now presented as Amortization of premiums on marketable securities, net of accretion and discounts. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. This may make it difficult or impossible to compare the Company’s financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include investments, fair value of the 2022 convertible note, embedded derivative and warrant liabilities, and stock-based compensation. Segment Reporting The Company manages its business on the basis of one reportable and operating segment. Operating segments are defined as components of an enterprise with separate financial information, and are evaluated regularly by the chief operating decision maker, which is the Company's Chief Executive Officer (“CEO”). The CEO decides how to allocate resources and assesses the Company’s performance based upon consolidated financial information. All of the Company's sales were made to customers (in USD) located in the U.S., Europe, and Asia through AEye, Inc. Of the $7,665 of net property and equipment as of December 31, 2022, $7,207 is located in the United States, $108 is located in Europe, and $350 is located in Asia. Cash, Cash Equivalents, and Marketable Securities The Company considers all highly liquid investments, such as treasury bills, commercial paper, certificates of deposit, and money market instruments with maturities of three months or less at the time of acquisition to be cash equivalents. Cash equivalents primarily consist of amounts held in interest-bearing money market accounts that are readily convertible to cash. Cash equivalents are stated at cost, which approximates fair market value. Marketable securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses in fair value of the available-for-sale (“AFS”) debt securities are reported in other comprehensive income (loss). When the AFS debt securities are sold, cost is based on the specific identification method, and the realized gains and losses are included in other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company considers all AFS debt securities as available for use to support current operations, including those with maturity dates beyond one year and are classified as current assets under marketable securities in the accompanying consolidated balance sheets. AFS debt securities included in marketable securities on the consolidated balance sheets consist of securities with original maturities greater than three months at the time of purchase. Interest on marketable securities is included within interest income. Restricted Cash Restricted cash of $2,150 and $2,150 as of December 31, 2022 and 2021, respectively consists of funds that are contractually restricted as to usage or withdrawal due to a contractual agreement. The Company has a letter of credit to the amount of $2,150 with Silicon Valley Bank as security for the payment of rent on its headquarters in Dublin, CA which require lease payments through 2026. The Company determines current or non-current classification of restricted cash based on the expected duration of the restriction. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities, and accounts receivable. The Company places its cash and cash equivalents with major financial institutions, which management assesses to be of high credit quality, to limit the exposure of each investment. The Company’s marketable securities have investment grade ratings when purchased which mitigates risk. The Company’s accounts receivables are derived from customers located in the U.S., Europe, and Asia. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions. The Company generally does not require collateral. The Company’s concentration of risk related to accounts receivable and accounts payable was determined by evaluating the number of customers and vendors accounting for 10% or more of accounts receivable (“AR”) and accounts payable (“AP”). As of December 31, 2022, AEye had four customers, each accounting for 10% or more of AR and two vendors, each accounting for 10% or more of AP. As of December 31, 2021, AEye had one customer accounting for 10% or more of AR and two vendors accounting for 10% or more of AP. During the years ended December 31, 2022 and 2021, the Company did not have any write offs of accounts receivable and at December 31, 2022 and 2021, did not record an allowance for doubtful accounts as all accounts receivable amounts were expected to be collected. For the years ended December 31, 2022 and 2021, revenue from the Company’s major customers representing 10% or more of total revenue was as follows: Twelve months ended December 31, 2022 2021 Customer A 51 % 55 % Customer B 13 % * Customer C 10 % * *Customer accounted for less than 10% of total revenue in the period. Fair Value of Financial Instruments The Company defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. For additional discussion on fair value of financial instruments, see Note 3. Derivatives The Company accounts for derivative instruments in accordance with Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) Topic 815, Derivatives and Hedging (“ASC 815”). The Company’s objectives and strategies for using derivative instruments, and how the derivative instruments and related hedged items are accounted for affect the financial statements. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk. Terms of convertible debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value. An evaluation of specifically identified conditions is made to determine whether the fair value of the derivative issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results. For additional discussion of derivatives, see Note 3. Accounts Receivable, net Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. If necessary, accounts receivable are reduced by an allowance for doubtful accounts, which is the Company’s best estimate of the amount of credit losses inherent in its existing accounts receivable. The Company reviews the need for an allowance for doubtful accounts quarterly based on historical experience with each customer and the specifics of each arrangement. During the years ended December 31, 2022 and 2021, the Company did not have any write-offs and at December 31, 2022 and 2021 did not record an allowance for doubtful accounts as all accounts receivable amounts are expected to be collected. Inventories, net Inventories consist of raw materials, work in progress, and finished goods. Inventories are stated at the lower of cost and net realizable value and costs are computed under the standard cost method. Inventories that are not expected to be consumed in the next 12 months are classified within Other noncurrent assets. Prototype inventory cost consists of the associated raw material, direct labor, indirect labor and other overhead costs. The Company evaluates the need for inventory write-downs associated with obsolete, slow moving, and non-sellable inventory by reviewing estimated net realizable values on a periodic basis and records a provision for excess and obsolete inventory to adjust the carrying value of inventory as needed. The Company's inventory as of December 31, 2022 and 2021 was written down by $833 and $1,122, respectively, in order to record inventory at its estimated net realizable value. Deferred Transaction Costs The Company capitalized qualified legal, accounting, and other direct costs related to the Business Combination which were deferred until completion of the Business Combination. In August 2021, upon the completion of the Business Combination, all deferred costs were offset against proceeds from the Business Combination and the private investment in public equity (“PIPE”) financing. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 2 to7 years. Leasehold improvements are amortized over the shorter of the lease term or expected useful life of the improvements. Construction in progress is the construction or development of property and equipment that have not yet been placed in service. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized. Impairment of Long-Lived Assets The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. There are no impairment charges recorded in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021. Warrant Liability The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance. The warrants assumed in connection with the 2022 convertible note are accounted for in accordance with ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, under which the warrants do not meet the criteria for equity treatment and must be recorded as liabilities. The Private Placement Warrants issued in connection with the IPO are classified as liabilities. The Company adjusts the warrants to fair value at each reporting period. The warrant liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the consolidated statements of operations. Leases The Company determines if an arrangement is or contains a lease at inception. The Company evaluates the classification of leases at commencement, and, as necessary, at modification. Operating leases, consisting of office leases, are included in Right-of-use ("ROU") assets, Accrued expenses and other current liabilities Convertible Notes The Company elected to early adopt Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The Company has elected to apply the fair value measurement option to the 2022 convertible note on the date that the Company first recognized the convertible note on September 15, 2022. The Company acknowledges that its election to apply the fair value option is irrevocable. The Company recognized costs incurred upon issuance of the 2022 convertible note as an expense in its consolidated income statement for the twelve months ended December 31, 2022. The 2022 convertible note is classified and presented as a current liability on the Consolidated Balance Sheet as of December 31, 2022. Changes in fair value are recorded in the consolidated statements of operations and changes in fair value related to credit risk are recorded in other comprehensive loss. The Company reports interest expense, including accrued interest, related to this convertible debt under the fair value option, within the change in fair value of convertible notes in the consolidated statement of operations. Revenue Recognition The Company generates revenues from the sale of prototypes and from development arrangements with automakers and suppliers to automakers. Under FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company accounts for such arrangements as contracts with customers and accordingly recognizes revenue by applying the following steps: • Identification of the contract, or contracts, with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue from the sale of prototypes is generally recognized at a point in time when control of the goods is transferred. Certain prototype sales contracts include services to install and commission or customize the prototypes for customers. Revenues from these services are categorized as prototype revenue and recognized either over time as the services are being performed, or at a point in time, depending on the nature of the services and whether the criteria for recording revenue over time are met in accordance with ASC 606. Revenue from development arrangements is either recognized at a point in time or over time depending on the performance obligations in the contract. For performance obligations that are satisfied over time, such as services which require engineering and development based on customer requirements, the Company recognizes revenue using an input method based on contract costs incurred to date compared to total estimated contract costs. See Note 18, Revenue, for additional information related to the application of ASC 606 to the Company’s primary revenue streams. Sales taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from revenues in the consolidated statements of operations and comprehensive loss. Arrangements with Multiple Performance Obligations When a contract involves multiple performance obligations, the Company accounts for individual products and services separately if the customer can benefit from the product or service on its own or with other resources that are readily available to the customer and the product or service is separately identifiable from other promises in the arrangement. The consideration is allocated between separate performance obligations in proportion to their estimated standalone selling price (SSP). The SSP reflects the price the Company would charge for a specific product or service if it were sold separately in similar circumstances and to similar customers. If the selling price is not directly observable, the Company determines SSP using information that may include other observable inputs, such as the cost plus margin approach, to estimate SSP. In instances where SSP is not directly observable, the Company determines SSP using information that may include other observable inputs such as expected costs plus margin, or uses the residual approach for performance obligations whose SSP is highly variable or uncertain. The Company provides standard product warranties for a term of typically one year to ensure that its products comply with agreed-upon specifications. Standard warranties are considered to be assurance type warranties and are not accounted for as separate performance obligations. Estimated future warranty costs are accrued and charged to cost of sales in the period that the related revenue is recognized. These estimates are based on historical warranty experience and any known or expected changes in warranty exposure, such as trends of product reliability and costs of repairing and replacing defective products. The Company assesses the adequacy of its recorded warranty liabilities on a quarterly basis and adjusts the amounts as necessary. Warranty costs are included within accrued expenses and other liabilities on the consolidated balance sheets. Refer to Note 10 for further information on warranty reserve amounts. Other Policies, Judgments and Practical Expedients Contract assets and liabilities. Contract assets primarily represent revenues recognized for performance obligations that have been satisfied but for which amounts have not been billed. The Company did not have any contract assets as of December 31, 2022. Contract liabilities relate to deferred revenue. Deferred revenue consists of amounts that have been invoiced and/or cash received but for which revenue has not been earned. This generally includes unrecognized revenue balances for development arrangements. Deferred revenue that will be realized during the succeeding 12-month period is recorded within current liabilities and the remaining deferred revenue is recorded as noncurrent liabilities. Right of return. The Company’s general terms and conditions for its contracts do not contain a right of return that allows the customer to return products and receive a credit. Therefore, the Company does not estimate returns and generally recognizes revenue at contract price upon product shipment or delivery. Significant financing component. In certain arrangements, the Company receives payment from a customer either before or after the performance obligation has been satisfied. The expected timing difference between the payment and satisfaction of performance obligations for all of the Company’s contracts is one year or less; therefore, the Company applies a practical expedient and does not consider the effects of the time value of money on transaction price. The Company’s contracts with customer prepayment terms do not include a significant financing component because the primary purpose is not to receive financing from the customers. Contract modifications. The Company may modify contracts to offer customers additional products or services. Each of the additional products and services are generally considered distinct from those products or services transferred to the customer before the modification. The Company evaluates whether the contract price for the additional products and services reflects the standalone selling price as adjusted for facts and circumstances applicable to that contract. In these cases, the Company accounts for the additional products or services as a separate contract. In other cases where the pricing in the modification does not reflect the standalone selling price as adjusted for facts and circumstances applicable to that contract, the Company accounts for the additional products or services as part of the existing contract primarily on a prospective basis. Judgments and estimates. Accounting for contracts recognized over time under ASC 606 involves the use of various techniques to estimate total contract revenue and costs. Due to uncertainties inherent in the estimation process, it is possible that estimates of costs to complete a contract will be revised in the near-term. The Company reviews and updates its contract-related estimates quarterly, and records adjustments as needed. For those performance obligations for which revenue is recognized using a cost-to-cost input method, changes in total estimated costs, and related progress towards complete satisfaction of the performance obligation, are recognized in the period in which the revisions to the estimates are made. Cost of Revenue Cost of revenue primarily consists of costs directly associated with the production of those prototypes that are held for sale and certain costs associated with development arrangements. Such costs for prototypes are direct materials, direct labor, indirect labor, warranty expense, and allocation of overhead. Direct and indirect labor includes personnel-related costs and packaging and procurement respectively associated with the production of prototypes. Other costs such as indirect manufacturing costs are recognized in research and development and general and administrative expenses on the consolidated statements of operations and comprehensive loss. Costs associated with development arrangements include the direct costs and allocation of overhead costs involved in the execution of the contract. Research and Development Expenses Research and development expenses include personnel costs (including salaries, benefits, bonuses, and stock-based compensation), new hardware and software materials to the extent no future economic benefits are expected, other related expenses such as lab equipment, third party development-related contractors, and allocated overhead expenses. Substantially all the R&D expenses are related to the development of new products and services, including contract development expenses. They are expensed as incurred and included in the consolidated statements of operation and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based awards based on estimated grant-date fair values. The Company uses the straight-line attribution method to allocate compensation cost to reporting periods over each awardee’s requisite service period, which is generally the vesting period of the award. The Company measures nonemployee awards at the date of grant, which generally is the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The Company’s policy is to recognize the effect of forfeitures in the period they occur. The grant-date fair value of the restricted stock units, or “RSUs,” is equal to the fair market value of the Company’s common stock on the grant date. The grant-date fair value for stock options and stock purchase rights under the employee stock purchase plan ("ESPP") is estimated using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of subjective assumptions, including the option’s expected term and the price volatility of the underlying stock. Stock options and RSUs for all periods prior to the Business Combination have been retroactively restated to give effect to the recapitalization. Refer to Note 2 for further discussion of the equity recapitalization resulting from the Business Combination. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of their net recorded amount, an adjustment to the deferred tax asset valuation allowance would be made to reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”) on the basis of a two-step process in which determinations are made (1) whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets. As of and for the year ended December 31, 2022 and 2021 there were no interest or penalties recorded. Net Loss per Share Basic net loss per share is computed using net loss available to common stockholders divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the dilutive effects of stock options, restricted stock units, preferred stock, stock to be issued under the ESPP, convertible notes, and warrants outstanding during the period to the extent such securities would not be anti-dilutive and is determined using the if-converted and treasury stock methods. The Company calculates weighted average number of common shares outstanding during the period using the Company’s Class A common stock outstanding. As the merger has been accounted for as a reverse capitalization, the consolidated financial statements of the merged entity reflects the continuation of the pre-merger AEye Technologies financial statements, which has been retroactively adjusted to the earliest period presented to reflect the legal capital of the legal acquirer, CF III. As a result, net loss per share was also restated for periods ended prior to the Business Combination. See Note 2 for details on this recapitalization and Note 16 for the retroactive restatement of net loss per share. Basic and diluted net loss per share attr

Recapitalization

Recapitalization	12 Months Ended
Recapitalization	Dec. 31, 2022
Reverse Recapitalization [Abstract]
Recapitalization	RECAPITALIZATION As discussed in Note 1, on August 16, 2021, AEye Technologies and CF III closed the Business Combination, with AEye Technologies surviving the Business Combination as a wholly owned subsidiary of CF III. As part of the closing of the Business Combination, CF III changed its name to AEye, Inc. (the “Combined Entity”). Immediately prior to the closing of the Business Combination, the Company’s certificate of incorporation was amended and restated to, among other things, increase the total number of authorized shares of capital stock to 301,000,000 shares, of which 300,000,000 shares were designated common stock, $0.0001 par value per share, and of which 1,000,000 shares were designated preferred stock, $0.0001 par value per share. The Business Combination is accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with US GAAP. Under this method of accounting, AEye Technologies was treated as the accounting acquirer and CF III was treated as the acquired company for financial reporting purposes under FASB ASC Topic 805, Business Combinations (“ASC 805”). This determination is primarily based on AEye Technologies’ stockholders comprising a majority of the voting power of the Combined Entity, and having the ability to nominate the majority of the governing body of the Combined Entity, AEye Technologies’ senior management comprising the senior management of the Combined Entity and AEye Technologies’ operations comprising the ongoing operations of the Combined Entity. Accordingly, for accounting purposes, the financial statements of the Combined Entity represented a continuation of the financial statements of AEye Technologies and the Business Combination was treated as the equivalent of AEye Technologies issuing stock for the net assets of CF III, accompanied by a recapitalization. The net assets of CF III are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of AEye Technologies in future reports of the Combined Entity. Loss per share and stockholders’ equity (deficit), prior to the Business Combination, have been retroactively converted into 3.7208 shares (the “Exchange Ratio”). Immediately prior to the closing of the Business Combination, all outstanding principal and unpaid accrued interest of the 2020 Notes were ultimately converted into 5,584,308 shares of AEye Technologies’ common stock and subsequently converted to Class A common stock of the Company (see Note 14). Separately, each issued and outstanding share of AEye Technologies’ 16,383,725 redeemable convertible preferred stock was converted into shares of AEye Technologies’ common stock based on a one-to-one ratio. The consolidated financial statements are accounted for with a retrospective application of the Business Combination that results in 16,383,725 shares of redeemable convertible preferred stock converting into common stock of the Company. Upon the closing of the Business Combination, each share of AEye Technologies common stock issued and outstanding was canceled and converted into the right to receive 3.7208 shares of CF III’s common stock (the “Per Share Merger Consideration”). Immediately prior to the closing of the Business Combination, the Board approved the net-exercise of common stock warrants and Series A preferred warrants which provides for the cashless exercise of 61,612 common stock warrants into 57,770 shares of AEye Technologies common stock and 7,353 Series A preferred warrants into 6,949 shares of AEye Technologies common stock at the Transaction Price of 37.21 per share. Upon the Closing, the combined 64,719 shares were cancelled and exchanged for 240,806 shares of the Company’s Class A common stock, after giving effect to the Exchange Ratio. Immediately prior to the closing of the Business Combination, CF III’s amended and restated certificate of incorporation, dated November 12, 2020 (the “Charter”), was further amended and restated to eliminate the Class B common stock (after giving effect to the conversion of each outstanding share of Class B common stock immediately prior to the closing of the Business Combination into one share of Class A common stock). PIPE Subscription Agreement Contemporaneously with the execution of the Merger Agreement, CF III entered into separate PIPE Subscription Agreements in a private placement with a number of PIPE investors, pursuant to which the PIPE Investors agreed to purchase, and CF III agreed to sell to the PIPE Investors, an aggregate of 22,000,000 shares of common stock, for a purchase price of $10.00 per share and an aggregate purchase price of $220,000. CF III also entered into a PIPE Subscription Agreement for 500,000 shares of common stock, for a purchase price of $10.00 per share and an aggregate purchase price of $5,000 with an investor who defaulted on the Closing under the PIPE Subscription Agreement. The Company has initiated litigation to enforce the terms of that investor's PIPE Subscription Agreement. Redemption Certain CF III shareholders exercised their right to redeem certain of their outstanding shares for cash, resulting in the redemption of 19,355,365 shares of CF III Class A common stock for an aggregate payment of $195,498, at a redemption price of $10.10 per share based on the Trust Account balance as of August 11, 2021. Public and Private Placement Warrants CF III Warrants issued in connection with the IPO (“Public Warrants”) and in connection with the private placement units held by the Sponsor (“Private Placement Warrants”) to purchase shares of the Company’s common stock, at an exercise price of $11.50 per share, remained outstanding after the closing of the Business Combination. The warrants became exercisable 30 days after the completion of the Business Combination, subject to other conditions, including with respect to the effectiveness of a registration statement covering the shares of common stock underlying such warrants, an d will expir e five years af ter the completion of the Business Combination or earlier upon redemption or liquidation. The Public Warrants are classified as equity and valued based on the instrument’s publicly listed trading price. The Private Placement Warrants are classified as liabilities and measured at fair value, with changes in fair value each period reported in the consolidated statements of operations and comprehensive loss. The Company uses the Public Warrants listed trading price to value the Private Placement Warrants each reporting period. Transaction Costs In connection with the Business Combination, the Company incurred direct and incremental costs of approximately $52,661 related to the equity issuance, consisting primarily of investment banking, legal, accounting, and other professional fees, which were recorded to additional paid-in capital as a reduction of proceeds upon the closing of the Business Combination. Transaction costs that were not directly related to the Business Combination of approximately $2,198 were expensed. Transaction Proceeds Upon closing of the Business Combination, the Company received gross proceeds of $256,811 from the Business Combination and PIPE financing, offset by offerings costs of $52,661. The following table reconciles the elements of the Business Combination to the consolidated statements of cash flows and the consolidated statements of changes in stockholders’ deficit for period ended December 31, 2021 (in thousands, except share data): Cash - CF III's trust and cash (net of redemption) $ 36,811 Cash - Private offering 220,000 Less: transaction costs and advisory fees paid (52,661) Net Business Combination and private offering $ 204,150 The number of shares of common stock issued immediately following the closing of the Business Combination were: CF III Class A common stock, outstanding prior to Business Combination 23,000,000 Less: redemption of CF III Class A common stock 19,355,365 Class A common stock of CF III 3,644,635 CF III founder shares 5,750,000 CF III Private Placement shares 500,000 CF III Shares issued in PIPE 22,000,000 Business Combination and PIPE shares 31,894,635 Legacy AEye shares 122,509,667 August 16, 2021 154,404,302 The number of Legacy AEye shares was determined as follows: AEye shares AEye shares, effected for Exchange Ratio Balance at December 31, 2019 11,283,838 41,984,908 Recapitalization applied to Convertible preferred stock outstanding at December 31, 2019 16,383,725 60,960,574 Exercise of common stock options - 2020 504,524 1,877,233 Repurchase of common stock - 2020 (950,352) (3,536,070) Exercise of common stock options - 2021 (pre-Closing) 54,859 204,119 Conversion of Convertible Notes and Accrued Interest – 2021 5,584,308 20,778,097 Exercise of common stock and Series A preferred stock warrants - 2021 64,719 240,806 Total 122,509,667

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities is determined in accordance with the fair value hierarchy established in FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels: Level 1 —Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 —Observable inputs, other than Level 1 inputs, which are observable either directly or indirectly or can be corroborated by observable market data using quoted prices for similar assets or liabilities. Level 3 —Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company's financial instruments that are not re-measured at fair value include accounts receivable, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities, 2020 convertible notes, and long-term debt. The carrying values of these financial instruments approximate their fair values. The Company’s financial assets and liabilities measured at fair value on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): Fair Value Measured as of December 31, 2022 Using: Adjusted Cost Unrealized losses Fair Value Cash and Cash Equivalent Marketable Securities Assets Level 1 Money market funds $ 14,253 $ — $ 14,253 $ 14,253 $ — Level 2 Asset-backed securities $ 3,507 $ (119) $ 3,388 $ — $ 3,388 Corporate bonds 22,139 (240) 21,899 — 21,899 Commercial paper 20,760 — 20,760 — 20,760 U.S. Government securities 29,983 (895) 29,088 — 29,088 Total financial assets $ 90,642 $ (1,254) $ 89,388 $ 14,253 $ 75,135 Liabilities Level 2 Private placement warrant liability $ — $ — $ 7 $ — $ — Level 3 Convertible notes — — 8,594 — — Derivative warrant liability — — 119 — — Total financial liabilities $ — $ — $ 9,200 $ — $ — Fair Value Measured as of December 31, 2021 Using: Adjusted Cost Unrealized losses Fair Value Cash and Cash Equivalent Marketable Securities Assets Level 1 Money market funds $ 4,863 $ — $ 4,863 $ 4,863 $ — Level 2 Asset-backed securities $ 26,491 $ (68) $ 26,423 $ — $ 26,423 Corporate bonds 48,643 (150) 48,493 — 48,493 Commercial paper 45,145 — 45,145 — 45,145 U.S. Government securities 29,936 (173) 29,763 — 29,763 Total financial assets $ 155,078 $ (391) $ 154,687 $ 4,863 $ 149,824 Liabilities Level 2 Private placement warrant liability $ — $ — $ 155 $ — $ — Total financial liabilities $ — $ — $ 155 $ — $ — As of December 31, 2022, the Company’s financial assets and liabilities subject to fair value procedures were comprised of the following: Money Market Funds: The Company holds financial assets consisting of money market funds. These securities are valued using observable inputs, such as quoted prices in active markets for identical assets or liabilities. Marketable Securities : The Company holds financial assets consisting of fixed-income U.S. government agency securities, corporate bonds, commercial paper and asset-backed securities. The securities are valued using prices from independent pricing services based on quoted prices of identical instruments in less active or inactive markets. Additionally, quoted prices of similar instruments in active market or industry models using data inputs such as interest rates and prices that can be directly observed or corroborated in active markets are used to value marketable securities. 2022 Convertible Note : On September 15, 2022, the Company entered into a convertible note agreement with a face value of $10,500,000 (the "2022 Note"). The Company elected the fair value option to account for the 2022 Note. The fair value estimate of the 2022 Note was based on a binomial lattice model, which represents Level 3 measurements. Significant assumptions include the discount rate used in the model, remaining term, stock price, and volatility. The discount rate is derived from the estimated credit spread and the risk-free interest rate, which is based on interpolated U.S. Treasury rates, commensurate with a similar term to the Note. The remaining term is calculated as the remaining contractual term of the Note. The stock price is based on the publicly traded price of our Common Stock as of the measurement date. The Company estimated the volatility for the Note based on the historical and implied volatilities of the Company's publicly traded common stock under the symbol "LIDR." The changes in fair value are recognized in other income (expense) for each reporting period. Refer to Note 12 for details of the terms and conditions of the 2022 Note. Derivative Warrant Liability : The Company’s derivative warrant liability includes the warrants that were issued by the Company as part of the 2022 Note. The warrants are recorded on the consolidated balance sheets at fair value. The fair value is based on unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The fair value estimate of the warrants was based on a Monte-Carlo simulation model. Inherent in a Monte-Carlo simulation model are assumptions related to price, volatility, risk-free interest rate, term to expiration, and dividend yield. The price is based on the publicly traded price of our Common Stock as of the measurement date. The Company estimated the volatility for the warrants based on the historical and implied volatilities of the Company's publicly traded common stock under the symbol "LIDR." The risk-free interest rate is based on interpolated U.S. Treasury rates, commensurate with a similar term to the warrants. The term to expiration was calculated as the contractual term of the warrants of 4 years. Finally, the Company does not anticipate paying a dividend. Any changes in these assumptions can change the valuation significantly. Changes in fair value are recognized in other income (expense) for each reporting period. Derivative Warrant Liability is included within other noncurrent liabilities on the consolidated balance sheets. Private Placement Warrant Liability : The Private Placement Warrants are recorded on the consolidated balance sheets at fair value. The fair value is based on observable Level 2 inputs, specifically, the observable input of AEye public warrants traded under the symbol "LIDRW". Any changes in the fair value of the liability are reflected in other income (expense), net, on the consolidated statements of operations and comprehensive loss. Private Placement Warrant liability is included within other noncurrent liabilities on the consolidated balance sheets. For the years ended December 31, 2022 and 2021, there were no transfers between Level 1 and Level 2 inputs. The following table presents a summary of the changes in fair value of the Company’s Level 3 financial instruments for the year ended December 31, 2022: 2022 Convertible Note Derivative Warrant Liability Total Balance at December 31, 2021 $ — $ — $ — Additions 9,512 488 10,000 Payments or conversions (1,474) — (1,474) Change in fair value included in other income (expense) 531 (369) 162 Change in fair value due to instrument specific credit risk included in other comprehensive income 25 — 25 Balance at December 31, 2022 $ 8,594 $ 119 $ 8,713 The key inputs into the binomial-lattice model for the convertible note valued at December 31, 2022 are as follows: December 31, 2022 Remaining term (years) 1.2 Expected volatility 90.4 % Risk-free interest rate 4.6 % Dividend yield — % Estimated credit spread 37.7 % The key inputs into the Monte-Carlo simulation model for the derivative warrant liability valued at December 31, 2022 are as follows: December 31, 2022 Expected term (years) 3.7 Expected volatility 90.4 % Risk-free interest rate 4.1 % Dividend yield — % Exercise price $ 3.50

Cash, Cash Equivalents, and Res

Cash, Cash Equivalents, and Restricted Cash	12 Months Ended
Cash, Cash Equivalents, and Restricted Cash	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, and Restricted Cash	CASH, CASH EQUIVALENTS, AND RESTRICTED CASH Cash, cash equivalents (which consists entirely of money market funds) and restricted cash as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Cash and cash equivalents $ 19,064 $ 14,183 Restricted cash 2,150 2,150 Total cash, cash equivalents, and restricted cash $ 21,214 $ 16,333

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventory, net of write-downs, as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Raw materials $ 2,022 $ 1,544 Work in-process 2,484 2,447 Finished goods 47 94 Total inventory, net $ 4,553 $ 4,085 The Company also had $1,491 and $0 of non-current inventory (raw materials) classified within Other noncurrent assets on the consolidated balance sheet as of December 31, 2022 and December 31, 2021, respectively.

Prepaid and Other Current Asset

Prepaid and Other Current Assets	12 Months Ended
Prepaid and Other Current Assets	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and Other Current Assets	PREPAID AND OTHER CURRENT ASSETS Prepaid and other current assets as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Prepaid expenses $ 4,203 $ 3,980 Demonstration units 281 224 Advances to suppliers 984 745 Other 713 102 Total prepaid and other current assets $ 6,181 $ 5,051

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2022
Leases [Abstract]
Leases	LEASES The Company primarily leases office facilities in Northern California under noncancelable operating leases expiring at various dates through November 2026. Some of the Company's leases include options to renew, with renewal terms that, if exercised by the Company, extend the lease term from two The components of operating lease expenses for the twelve months ended December 31, 2022 were as follows (in thousands): Twelve months ended December 31, 2022 Operating lease cost $ 2,382 Variable lease cost 241 Total operating lease cost $ 2,623 Supplemental cash flow information for the twelve months ended December 31, 2022 were as follows (in thousands): December 31, 2022 Cash paid for operating leases included in operating cash flows $ (1,341) Supplemental balance sheet information related to operating leases was as follows (in thousands): December 31, 2022 Operating lease right-of-use assets $ 15,502 Operating lease liabilities: Operating lease liabilities, current $ 2,455 Operating lease liabilities, non-current 16,681 Total operating lease liabilities $ 19,136 December 31, 2022 Weighted average remaining lease term (in years) 9.26 Weighted average discount rate 5.35 % Maturities of lease liabilities were as follows (in thousands). Years ended - December 31: 2023 $ 2,516 2024 2,570 2025 2,583 2026 2,660 2027 2,701 Thereafter 11,116 Total lease payments 24,146 Less amount to discount to present value (5,010) Present value of lease liabilities $ 19,136 Disclosures under ASC 840, Leases The company recognizes rent expense on a straight-line basis over the lease period. Rent expense is principally the leased office space and was $1,876 within operating expenses in the consolidated statements of operations and comprehensive loss for the twelve months ended December 31, 2021. Deferred rent liabilities, including unamortized leasehold improvement incentives was $3,637 as of December 31, 2021 within the consolidated balance sheet. Future minimum payments as of December 31, 2021 under the noncancellable operating leases are as follows (in thousands): Operating Leases Years ended: 2022 2,393 2023 2,341 2024 2,412 2025 2,484 2026 and after 2,340 Total minimum lease payments 11,970

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	PROPERTY AND EQUIPMENT, NET Property and equipment, net as of December 31, 2022 and 2021 consists of the following (in thousands): As of December 31, 2022 2021 Machinery and equipment $ 2,528 $ 1,444 Computers, software and related equipment 432 268 Office furniture and equipment 651 341 Vehicles 846 342 Leasehold improvements 4,830 4,725 Construction in progress 1,401 213 Total property and equipment 10,688 7,333 Less accumulated depreciation and amortization (3,023) (2,204) Property and equipment, net $ 7,665 $ 5,129 Depreciation and amortization expense related to property and equipment amounted to $1,422 and $1,014 recognized within research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021. $604 of property and equipment was disposed in the year ended December 31, 2022. Disposals of property and equipment were not material the year ended December 31, 2021.

Other Noncurrent Assets

Other Noncurrent Assets	12 Months Ended
Other Noncurrent Assets	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Noncurrent Assets	OTHER NONCURRENT ASSETS Other noncurrent assets as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Non-current inventory $ 1,491 $ — Long-term prepaid expenses 901 1,376 Security deposits 81 133 Total other noncurrent assets $ 2,473 $ 1,509

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
Accrued Expenses and Other Current Liabilities	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Accrued purchases and other $ 4,092 $ 1,947 Operating lease liabilities - current 2,455 — Accrued bonuses 1,022 3,408 Accrued payroll 1,148 957 Accrued payroll taxes 526 1,547 Warranty reserve 480 275 Income tax payable 41 — Deferred rent - current — 605 Total accrued expenses and other current liabilities $ 9,764 $ 8,739

Borrowings

Borrowings	12 Months Ended
Borrowings	Dec. 31, 2022
Debt Disclosure [Abstract]
Borrowings	BORROWINGS Silicon Valley Bank Financing Facility On April 26, 2021, the Company entered into a loan and security agreement (the “Loan Agreement”) with an affiliate of Silicon Valley Bank (“SVB” or the “Lender”) in connection with the non-binding term sheet for a financing facility of up to $10,000 entered into on March 18, 2021. Under the Loan Agreement, the Lender was obligated to make a term loan advance to the Company of $4,000. Subject to the terms and conditions of the Loan Agreement and, upon the Company’s request, the Lender was obligated to make one term loan advance to the Company of $6,000. The interest rate on the term loan advance is calculated at 8% per annum and payable monthly, in arrears. Upon entering the Loan Agreement, $4,000 was drawn. On May 13, 2021, the additional $6,000 was drawn. The balance of $10,540 for the financing facility, including interest, was repaid on August 20, 2021. Silicon Valley Bank Credit Facility On August 16, 2019, the Company entered into a loan and security agreement with SVB. Borrowings under this facility are secured by substantially all the Company’s assets, excluding intellectual property. The term loan’s borrowings are subject to certain financial covenants and restrictions. The Company complied with all financial covenants and restrictions. The balance of $2,333 for the term loan was repaid on September 7, 2021. Paycheck Protection Program (PPP) Loan On June 19, 2021, the Company received notice of the Paycheck Protection Program (PPP) forgiveness payment made to SVB by the Small Business Administration in the amount of $2,270 in principal and $27 in interest. This amount represents the forgiveness of the total PPP loan the Company received in 2020 under the PPP Loan provisions of the Coronavirus Aid, Relief and Economic Security (CARES) Act. As of December 31, 2022 and 2021, there were no borrowings outstanding. 2020 Convertible Notes During 2020, the Company entered into various convertible note agreements (“2020 Notes”) under which the Company may issue convertible equity instruments having an aggregate principal amount of up to $40,000, a 3% accruing dividend (“accrued interest”) and a maturity date of October 31, 2021. In connection with the Business Combination on August 16, 2021, all outstanding principal of $38,045 and unpaid accrued interest on the 2020 Notes were converted into AEye Technologies’ preferred stock and subsequently were converted into 20,778,097 shares of the Company’s Class A common stock. Accordingly, at December 31, 2022 and December 31, 2021, the convertible notes balance was $0. 2022 Convertible Note On September 14, 2022, the Company entered into a Securities Purchase Agreement with an investor allowing for the sale and issue of two convertible notes, each with a principal balance of $10,500 and cash proceeds of $10,000, for a total of $20,000 in proceeds between the two issuances (each, a "Note Closing"). The first Note Closing ("First Closing") occurred on September 15, 2022, and the Company entered into a Senior Unsecured Convertible Note with the investor pursuant to which the Company issued to the investor one convertible note ("2022 Note") with a principal balance of $10,500 for cash proceeds of $10,000. As part of the First Closing, the Company also issued warrants to the investor - see Note 14 for further details. The second Note Closing ("Second Closing") may occur, at the Company's option, no earlier than the ninetieth (90th) calendar day after the First Closing, provided that the Company meets certain equity conditions. Additional warrants would be issued to the investor upon the Second Closing. The 2022 Note bears interest at an annual rate of 5.0%, in addition to an original issue discount of 4.76%, and has a maturity date of March 15, 2024 ("Maturity Date"). The interest may be settled in cash or shares at the option of the Company and is payable together with monthly redemptions of the outstanding principal amount of the Note. Beginning December 15, 2022, and the first of each subsequent month (each a "Monthly Redemption Date" or an "Installment Date"), the Company shall redeem the Monthly Redemption Amount until the 2022 Note is fully redeemed, payable in cash or, so long as certain equity conditions are met, shares of Common Stock at the option of the Company. The equity conditions that must be met in order for the Company to settle the Monthly Redemption Amount in shares include requirements for the daily volume weighted average price of the Company's Common Stock to exceed $0.33 and the average daily trading volume of the Company's Common Stock to exceed $500,000 for the twenty (20) trading days prior to the applicable Installment Notice Date (which is the sixth (6 th ) trading day prior to each Installment Date). The Monthly Redemption Amount, in most instances, will be 1/15 th of the original principal amount, plus any amount accelerated pursuant to the 2022 Note, accrued but unpaid interest, and late fees, if any. If the Company elects to settle such redemptions in shares of Common Stock, the number of shares to be settled shall be based on an Installment Conversion Price equal to the lower of (i) $2.50 or (ii) 95% of the lowest daily volume weighted average price of the Common Stock during the five (5) trading days immediately preceding the applicable Monthly Redemption Date. If the Company elects to settle redemptions in cash, the Monthly Redemption Amount shall include a 5% premium. The investor is permitted to accelerate up to four (4) Monthly Redemption Amounts in any calendar month (each, an "Acceleration," and each such amount, an "Acceleration Amount", and the Conversion Date of any such Acceleration, each an "Acceleration Date") at the Acceleration Conversion Price, subject to a $2,800 limit per month. The Acceleration Conversion Price shall be the lower of (i) the Installment Conversion Price for such current Installment Date or (ii) the greater of $0.30 and 95% of the lowest daily volume weighted average price of the Common Stock during the five (5) trading days immediately preceding the Acceleration Date. If, at any time while the 2022 Note is outstanding, the Company carries out one or more capital raises in excess of $5,000 in gross proceeds each, the investor shall have the right to require the Company to first use up to 30% of the gross proceeds of each capital raise to redeem all or a portion of the 2022 Note for an amount in cash (such amount, the "Mandatory Redemption Amount") equal to the sum of (a) 1.05 multiplied by the sum of the principal amount subject to the Mandatory Redemption and accrued but unpaid interest and (b) 1.00 multiplied by the sum of the Make-Whole amount, if any, and any other amounts, if any, then owing to the investor in respect of the 2022 Note (a "Mandatory Redemption"). The Make-Whole amount is defined as an amount equal to the additional interest that would accrue under the 2022 Note assuming for calculation purposes that the principal of the 2022 Note remained outstanding through the Maturity Date. The 2022 Note may not be converted into Common Stock to the extent such conversion would result in the investor and its affiliates having beneficial ownership of more than 9.99% of our then outstanding shares of Common Stock. The Company and investor entered into a registration rights agreement (the “Registration Rights Agreement”) to which the Company is required to file a registration statement registering the resale by the investor of any shares of the Company’s common stock issuable upon conversion, including the resale of shares issuable upon exercise of the associated warrants. The Company is required to meet certain obligations with respect to the timeliness of the filing and effectiveness of the registration statement. The Company filed such registration statement on October 19, 2022, which was declared effective by the U.S. Securities and Exchange Commission on October 27, 2022. The Company elected to apply the fair value option to the measurement of the 2022 Note. As a result of adopting the fair value option no embedded derivatives should be bifurcated from the 2022 Note. The Company classifies the 2022 Note as a liability at fair value and will remeasure the 2022 Note to fair value at each reporting period. The total proceeds received from the investor of $10,000 should be allocated between the 2022 Note and the related warrants issued using the relative fair value method at issuance date. This resulted in an initial fair value of $9,512 being allocated to the 2022 Note, and $488 allocated to the associated warrants (see Note 3 for further details). The Company recorded total issuance costs of $474, representing placement agent and legal fees, within Interest expense and other on the consolidated statement of operations. The fair value measurement includes the assumption of accrued interest and expense and thus a separate amount is not reflected on the consolidated statement of operations. As of December 31, 2022, the 2022 Note has outstanding principal of $9,200 and is recorded as a current liability at fair value of $8,594. The Company evaluated the Second Closing and associated warrants to be a contingently issuable financial asset with a fair value of zero at inception in accordance with ASC 815-40 Contracts in an Entity's own Equity. The contingently issuable warrants are considered issued for accounting purposes - see Note 14 for further details. Embedded Derivative Liability As outlined in the indenture governing the 2020 Notes, the 2020 Notes are automatically convertible, contingent upon the occurrence of certain events, most notably a financing (a “Next Financing”), defined as the issuance and sale of additional preferred stock (“Financing Stock”). The redemption price is defined as a price per share equal to 90% of the price per share paid by the other purchasers of the Financing Stock sold in the Next Financing. The 2020 Notes are redeemable into the number of shares of Financing Stock needed to settle the aggregate amount of principal and unpaid interest owed to the holder of such notes, which is based on the ultimate price per share associated with the Financing Stock. Consequently, the 2020 Notes are considered stock settled debt. This redemption feature embedded in the 2020 Notes is considered to be a derivative that is required to be separately accounted for at fair value and subsequently remeasured to fair value at each reporting date. Accordingly, upon issuance of the 2020 Notes, the Company recognized the fair value associated with the embedded derivative which resulted in an embedded derivative liability of approximately $1,520, with an equal and offsetting debt discount. Upon the closing of the Business Combination on August 16, 2021, the embedded derivative was settled. Accordingly, at December 31, 2022 and December 31, 2021 , the fair value of the embedded derivative liability wa

Convertible Notes

Convertible Notes	12 Months Ended
Convertible Notes	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes	BORROWINGS Silicon Valley Bank Financing Facility On April 26, 2021, the Company entered into a loan and security agreement (the “Loan Agreement”) with an affiliate of Silicon Valley Bank (“SVB” or the “Lender”) in connection with the non-binding term sheet for a financing facility of up to $10,000 entered into on March 18, 2021. Under the Loan Agreement, the Lender was obligated to make a term loan advance to the Company of $4,000. Subject to the terms and conditions of the Loan Agreement and, upon the Company’s request, the Lender was obligated to make one term loan advance to the Company of $6,000. The interest rate on the term loan advance is calculated at 8% per annum and payable monthly, in arrears. Upon entering the Loan Agreement, $4,000 was drawn. On May 13, 2021, the additional $6,000 was drawn. The balance of $10,540 for the financing facility, including interest, was repaid on August 20, 2021. Silicon Valley Bank Credit Facility On August 16, 2019, the Company entered into a loan and security agreement with SVB. Borrowings under this facility are secured by substantially all the Company’s assets, excluding intellectual property. The term loan’s borrowings are subject to certain financial covenants and restrictions. The Company complied with all financial covenants and restrictions. The balance of $2,333 for the term loan was repaid on September 7, 2021. Paycheck Protection Program (PPP) Loan On June 19, 2021, the Company received notice of the Paycheck Protection Program (PPP) forgiveness payment made to SVB by the Small Business Administration in the amount of $2,270 in principal and $27 in interest. This amount represents the forgiveness of the total PPP loan the Company received in 2020 under the PPP Loan provisions of the Coronavirus Aid, Relief and Economic Security (CARES) Act. As of December 31, 2022 and 2021, there were no borrowings outstanding. 2020 Convertible Notes During 2020, the Company entered into various convertible note agreements (“2020 Notes”) under which the Company may issue convertible equity instruments having an aggregate principal amount of up to $40,000, a 3% accruing dividend (“accrued interest”) and a maturity date of October 31, 2021. In connection with the Business Combination on August 16, 2021, all outstanding principal of $38,045 and unpaid accrued interest on the 2020 Notes were converted into AEye Technologies’ preferred stock and subsequently were converted into 20,778,097 shares of the Company’s Class A common stock. Accordingly, at December 31, 2022 and December 31, 2021, the convertible notes balance was $0. 2022 Convertible Note On September 14, 2022, the Company entered into a Securities Purchase Agreement with an investor allowing for the sale and issue of two convertible notes, each with a principal balance of $10,500 and cash proceeds of $10,000, for a total of $20,000 in proceeds between the two issuances (each, a "Note Closing"). The first Note Closing ("First Closing") occurred on September 15, 2022, and the Company entered into a Senior Unsecured Convertible Note with the investor pursuant to which the Company issued to the investor one convertible note ("2022 Note") with a principal balance of $10,500 for cash proceeds of $10,000. As part of the First Closing, the Company also issued warrants to the investor - see Note 14 for further details. The second Note Closing ("Second Closing") may occur, at the Company's option, no earlier than the ninetieth (90th) calendar day after the First Closing, provided that the Company meets certain equity conditions. Additional warrants would be issued to the investor upon the Second Closing. The 2022 Note bears interest at an annual rate of 5.0%, in addition to an original issue discount of 4.76%, and has a maturity date of March 15, 2024 ("Maturity Date"). The interest may be settled in cash or shares at the option of the Company and is payable together with monthly redemptions of the outstanding principal amount of the Note. Beginning December 15, 2022, and the first of each subsequent month (each a "Monthly Redemption Date" or an "Installment Date"), the Company shall redeem the Monthly Redemption Amount until the 2022 Note is fully redeemed, payable in cash or, so long as certain equity conditions are met, shares of Common Stock at the option of the Company. The equity conditions that must be met in order for the Company to settle the Monthly Redemption Amount in shares include requirements for the daily volume weighted average price of the Company's Common Stock to exceed $0.33 and the average daily trading volume of the Company's Common Stock to exceed $500,000 for the twenty (20) trading days prior to the applicable Installment Notice Date (which is the sixth (6 th ) trading day prior to each Installment Date). The Monthly Redemption Amount, in most instances, will be 1/15 th of the original principal amount, plus any amount accelerated pursuant to the 2022 Note, accrued but unpaid interest, and late fees, if any. If the Company elects to settle such redemptions in shares of Common Stock, the number of shares to be settled shall be based on an Installment Conversion Price equal to the lower of (i) $2.50 or (ii) 95% of the lowest daily volume weighted average price of the Common Stock during the five (5) trading days immediately preceding the applicable Monthly Redemption Date. If the Company elects to settle redemptions in cash, the Monthly Redemption Amount shall include a 5% premium. The investor is permitted to accelerate up to four (4) Monthly Redemption Amounts in any calendar month (each, an "Acceleration," and each such amount, an "Acceleration Amount", and the Conversion Date of any such Acceleration, each an "Acceleration Date") at the Acceleration Conversion Price, subject to a $2,800 limit per month. The Acceleration Conversion Price shall be the lower of (i) the Installment Conversion Price for such current Installment Date or (ii) the greater of $0.30 and 95% of the lowest daily volume weighted average price of the Common Stock during the five (5) trading days immediately preceding the Acceleration Date. If, at any time while the 2022 Note is outstanding, the Company carries out one or more capital raises in excess of $5,000 in gross proceeds each, the investor shall have the right to require the Company to first use up to 30% of the gross proceeds of each capital raise to redeem all or a portion of the 2022 Note for an amount in cash (such amount, the "Mandatory Redemption Amount") equal to the sum of (a) 1.05 multiplied by the sum of the principal amount subject to the Mandatory Redemption and accrued but unpaid interest and (b) 1.00 multiplied by the sum of the Make-Whole amount, if any, and any other amounts, if any, then owing to the investor in respect of the 2022 Note (a "Mandatory Redemption"). The Make-Whole amount is defined as an amount equal to the additional interest that would accrue under the 2022 Note assuming for calculation purposes that the principal of the 2022 Note remained outstanding through the Maturity Date. The 2022 Note may not be converted into Common Stock to the extent such conversion would result in the investor and its affiliates having beneficial ownership of more than 9.99% of our then outstanding shares of Common Stock. The Company and investor entered into a registration rights agreement (the “Registration Rights Agreement”) to which the Company is required to file a registration statement registering the resale by the investor of any shares of the Company’s common stock issuable upon conversion, including the resale of shares issuable upon exercise of the associated warrants. The Company is required to meet certain obligations with respect to the timeliness of the filing and effectiveness of the registration statement. The Company filed such registration statement on October 19, 2022, which was declared effective by the U.S. Securities and Exchange Commission on October 27, 2022. The Company elected to apply the fair value option to the measurement of the 2022 Note. As a result of adopting the fair value option no embedded derivatives should be bifurcated from the 2022 Note. The Company classifies the 2022 Note as a liability at fair value and will remeasure the 2022 Note to fair value at each reporting period. The total proceeds received from the investor of $10,000 should be allocated between the 2022 Note and the related warrants issued using the relative fair value method at issuance date. This resulted in an initial fair value of $9,512 being allocated to the 2022 Note, and $488 allocated to the associated warrants (see Note 3 for further details). The Company recorded total issuance costs of $474, representing placement agent and legal fees, within Interest expense and other on the consolidated statement of operations. The fair value measurement includes the assumption of accrued interest and expense and thus a separate amount is not reflected on the consolidated statement of operations. As of December 31, 2022, the 2022 Note has outstanding principal of $9,200 and is recorded as a current liability at fair value of $8,594. The Company evaluated the Second Closing and associated warrants to be a contingently issuable financial asset with a fair value of zero at inception in accordance with ASC 815-40 Contracts in an Entity's own Equity. The contingently issuable warrants are considered issued for accounting purposes - see Note 14 for further details. Embedded Derivative Liability As outlined in the indenture governing the 2020 Notes, the 2020 Notes are automatically convertible, contingent upon the occurrence of certain events, most notably a financing (a “Next Financing”), defined as the issuance and sale of additional preferred stock (“Financing Stock”). The redemption price is defined as a price per share equal to 90% of the price per share paid by the other purchasers of the Financing Stock sold in the Next Financing. The 2020 Notes are redeemable into the number of shares of Financing Stock needed to settle the aggregate amount of principal and unpaid interest owed to the holder of such notes, which is based on the ultimate price per share associated with the Financing Stock. Consequently, the 2020 Notes are considered stock settled debt. This redemption feature embedded in the 2020 Notes is considered to be a derivative that is required to be separately accounted for at fair value and subsequently remeasured to fair value at each reporting date. Accordingly, upon issuance of the 2020 Notes, the Company recognized the fair value associated with the embedded derivative which resulted in an embedded derivative liability of approximately $1,520, with an equal and offsetting debt discount. Upon the closing of the Business Combination on August 16, 2021, the embedded derivative was settled. Accordingly, at December 31, 2022 and December 31, 2021 , the fair value of the embedded derivative liability wa

Interest Expense and Other

Interest Expense and Other	12 Months Ended
Interest Expense and Other	Dec. 31, 2022
Other Income and Expenses [Abstract]
Interest Expense and Other	INTEREST EXPENSE AND OTHER Interest expense and other for the years ended December 31, 2022 and 2021 consisted of the following (in thousands): Twelve months ended December 31, 2022 2021 Interest on term loan debt $ — $ 630 Interest on PPP loan — 11 Interest on 2020 convertible note — 700 Amortization of debt issuance costs — 725 2022 convertible note issuance costs 474 — Amortization of debt discount — 752 Amortization of premiums on marketable securities, net of accretion of discounts 778 456 Realized losses on redemptions of marketable securities 77 — Common stock purchase agreement transaction costs 29 1,583 Other 21 — Interest expense and other $ 1,379 $ 4,857

Stockholders' Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY The Company is authorized to issue 300,000,000 shares of common stock, par value $0.0001 per share. As of December 31, 2022, the Company had 163,099,124 shares of common stock issued and outstanding. Class A Common Stock — Class A common stock has the following rights: Voting rights: Each holder of Class A common stock will be entitled to one (1) vote in person or by proxy for each share of the Class A common stock held of record by such holder. The holders of shares of the Class A common stock will not have cumulative voting rights. Except as otherwise required in the Amended Charter or by applicable law, the holders of the Class A common stock vote together as a single class on all matters on which stockholders are generally entitled to vote. Dividend rights: Subject to any other provisions of the Amended Charter, each holder of Class A common stock will be entitled to receive, in proportion to the number of shares of the Class A common stock held, such dividends and other distributions in cash, stock or property of the Company when, as and if declared thereon by the Board from time to time out of assets or funds of the Company legally available therefor. Rights upon liquidation: In the event of any liquidation, dissolution or winding up (either voluntary or involuntary) of the Company, after payments to creditors of the Company that may at the time be outstanding, and subject to the rights of any holders of the Company preferred stock that may then be outstanding, holders of shares of the Class A common stock will be entitled to receive ratably, in proportion to the number of shares of the Class A common stock held by them, all remaining assets of the Company available for distribution. Preferred Stock — The Company has the authority, without stockholder approval, to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more class or series and to fix for each such class or series the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law. The issuance of the Company’s preferred stock could have the effect of decreasing the trading price of the Class A common stock, restricting dividends on the capital stock of the Company, diluting the voting power of the Class A common stock, impairing the liquidation rights of the capital stock of the Company, or delaying or preventing a change in control of the Company. Although the Company does not currently intend to issue any shares of preferred stock, the Company may choose to do so in the future. As discussed in Note 2, Recapitalization, the Company has retroactively adjusted the preferred shares issued and outstanding prior to August 16, 2021 to give effect to the Exchange Ratio established in the Merger Agreement to determine the number of shares of common stock into which they were converted. Upon the Closing on August 16, 2021, all of the outstanding shares of preferred stock were cancelled and exchanged for shares of the surviving Company’s Class A common stock at the Exchange Ratio of 3.7208, the exchange rate established in the Merger Agreement. August 16, 2021 (Closing) Preferred stock shares Exchange ratio Common stock shares Series A Convertible preferred stock (pre-combination) 9,226,734 3.7208 34,330,838 Series B Convertible preferred stock (pre-combination) 7,156,991 3.7208 26,629,736 Total 16,383,725 60,960,574 The Company is authorized to issue up to 1,000,000 shares of preferred stock, each with a par value of $0.0001 per share. As of December 31, 2022, no shares of preferred stock were issued and outstanding. Warrants — As of December 31, 2022, the Company had 166,666 Private Placement warrants and 7,666,656 Public warrants outstanding. Each warrant entitles the registered holder to purchase one share of the Company's common stock at a price of $11.50 per share. On September 15, 2022, in connection with the issuance of the 2022 Note, the Company issued warrants to the investor. The warrants are immediately exercisable and entitle the investor to purchase up to 1,750,000 shares of Common Stock at a price of $3.50 per share, subject to a four (4) year term. As of December 31, 2022, no shares were exercised pursuant to the warrants. Contingent Warrants - As of December 31, 2022, the Company had 1,750,000 contingently issuable warrants outstanding associated with the potential Second Closing under the Securities Purchase Agreement. These warrants will become exercisable by the investor if and when the Second Closing occurs. They will entitle the investor to purchase up to 1,750,000 shares of Common Stock at a price of $3.50 per share, subject to a four (4) year term. Tumim Stone Common Stock Purchase Agreement — On December 8, 2021, the Company entered into a Common Stock Purchase Agreement (the “CSPA”) and a Registration Rights Agreement with Tumim Stone Capital LLC (“Tumim Stone”). Under the terms and subject to the conditions of the CSPA, the Company has the right, but not the obligation, to sell to Tumim Stone, and Tumim Stone is obligated to purchase up to the lesser of (i) $125,000 of the Company’s common stock, or (ii) the Exchange Cap equal to 19.99% of the shares of the Company’s common stock outstanding immediately prior to the execution of the CSPA, unless the Company’s stockholders approve the issuance of shares in excess of the Exchange Cap, or the average price of all applicable sales of common stock to Tumim Stone under the CSPA equals or exceeds $4.9485. Upon the satisfaction of various commencement conditions, such as the filing of the registration statement which provides for the resale of such shares pursuant to the Registration Rights Agreement, the Company has sole discretion to initiate such sales of common stock over the period of 36 months commencing December 8, 2021. In all instances, the Company may not sell shares of its common stock to Tumim Stone under the CSPA if doing so would result in Tumim Stone beneficially owning more than 9.99% of its common stock. The purchase price per share to be purchased by Tumim is equal to the volume-weighted average price for common stock on the applicable purchase date multiplied by 0.9615 (to be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split, or similar transaction). The maximum number of shares the Company may sell to Tumim Stone on any single business day is the lesser of (i) $20,000 divided by the closing sale price of the common stock on the trading day immediately preceding the purchase date, and (ii) 0.15 multiplied by the average daily trading volume in common stock for the three In connection with the CSPA, the Company issued to Tumim Stone 302,634 restricted common shares in the Company. At issuance, the 302,634 shares of common stock had a fair value of $1,583 and were recorded to Interest expense and other in the Company’s consolidated statements of operations and comprehensive loss. The Company determined that the right to sell additional shares represents a freestanding put option under ASC 815 Derivatives and Hedging , and as such, the financial instrument was classified as a derivative asset with a fair value of zero at inception of the CSPA on December 8, 2021.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	12 Months Ended
ACCUMULATED OTHER COMPREHENSIVE LOSS	Dec. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	ACCUMULATED OTHER COMPREHENSIVE LOSS The changes in accumulated other comprehensive loss by component for the twelve months ended December 31, 2022 and 2021 are as follows (in thousands): Unrealized gains (losses) on available-for-sale securities Change in fair value due to instrument-specific credit risk Total Balance at December 31, 2020 $ — $ — $ — Other comprehensive loss, net of tax (391) — (391) Balance at December 31, 2021 (391) — (391) Other comprehensive loss before reclassifications, net of tax (940) (25) (965) Amounts reclassified from accumulated other comprehensive loss, net of tax 77 — 77 Net other comprehensive loss (863) (25) (888) Balance at December 31, 2022 $ (1,254) $ (25) $ (1,279) The $77 reclassified out of accumulated other comprehensive loss in the twelve months ended December 31, 2022 is included within Interest expense and other on the consolidated statement of operations.

Net Loss per Share

Net Loss per Share	12 Months Ended
Net Loss per Share	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share	NET LOSS PER SHARE The following table sets forth the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data): Twelve months ended December 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (98,714) $ (65,011) Denominator: Weighted average common shares outstanding- Basic 157,368,707 109,055,894 Dilutive effect of potential common shares — — Weighted average common shares outstanding- Diluted 157,368,707 109,055,894 Net loss per share attributable to common stockholders - Basic and Diluted $ (0.63) $ (0.60) Due to net losses for the years ended December 31, 2022 and 2021, basic and diluted net loss per share were the same, as the effect of all potentially dilutive securities would have been anti-dilutive. The following table sets forth the anti-dilutive common share equivalents for the periods listed: Twelve months ended December 31, 2022 2021 Warrants 9,583,322 7,833,332 Common stock options issued and outstanding 25,393,540 29,238,432 Unvested restricted stock units 12,771,096 7,434,743 Conversion of convertible notes 16,293,602 — ESPP 2,000,000 — Total 66,041,560 44,506,507

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION The Company has four equity incentive plans, the 2014 US LADAR Inc. Equity Incentive Plan (the “2014 Plan”), the 2016 Stock Plan (the “2016 Plan”), the 2021 Equity Incentive Plan (the “Incentive Plan”) and the 2022 Employee Stock Purchase Plan (the "ESPP"). On August 16, 2021, the Company’s 2014 Plan and 2016 Plan were terminated in connection with the closing of the Business Combination as defined in Note 1, but continue to govern the terms of outstanding equity awards that were granted prior to the termination of the plans. 2014 Plan and 2016 Plan The 2014 and 2016 Plan provide for the grant of incentive stock options to employees only and non-statutory stock options and RSUs to employees, directors, and consultants of the Company. As of August 16, 2021, the Company no longer grants equity awards pursuant to the 2014 Plan or 2016 Plan, and as of December 31, 2022, 1,741,689 RSUs were granted. Under the 2016 Plan, options to purchase common stock generally vest over four years with 25% vesting at the end of the first year and the rest vesting ratably over the next three years. RSUs generally vest 25% at the end of the first year with the remaining RSUs vesting ratably over the next three years or they vest ratably over the four years. Under the 2014 Plan, the vesting period for options to purchase common stock range from immediate to four years. Under each plan, the options expire ten years from the date of grant. In connection with the Closing on August 16, 2021, $1,500 was paid to a former executive as consideration for repurchasing 542,615 of his vested options under the Company's 2016 Plan. 2021 Equity Incentive Plan The Incentive Plan became effective immediately upon the Closing on August 16, 2021 and initially reserved 15,440,430 shares of common stock for issuance thereunder. The Incentive Plan includes an evergreen provision that provides for an annual increase in the number of shares of common stock available for issuance thereunder beginning on January 1, 2022 and ending on January 1, 2032, equal to 5% of the shares of the Company’s common stock outstanding on December 31, 2021 for the first year and by 3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year for each year thereafter, or a lesser number of shares as determined by the Board of Directors. After January 1, 2022, the Board of Directors authorized the addition of 7,743,413 shares of common stock to be added to the Incentive Plan for issuance. Under the Incentive plan, RSU’s vest depending on their vesting schedule. For newly hired employees, RSU’s generally vest 25% during the quarterly release date following the recipient’s one year anniversary of their start date. The remaining amounts generally vest quarterly over the next three years. For existing employees, these RSUs generally vest quarterly over three years. The fair value of the RSU is equal to the fair value of the Company’s common stock on the date of grant. As of December 31, 2022, 17,891,938 RSUs were granted to certain individuals under the Incentive Plan. 2022 Employee Stock Purchase Plan On May 10, 2022, the Company's stockholders approved the 2022 Employee Stock Purchase Plan (the "ESPP"), authorizing 2,000,000 shares of common stock to be reserved for issuance under the ESPP. The number of shares reserved and available for issuance under the ESPP shall be cumulatively increased by the 1% of the number of shares issued and outstanding on December 31 of the preceding calendar year for each year thereafter, or a lesser number of shares as determined by the Board of Directors. The ESPP provides an offering period of 24 months, with four purchase periods that are generally six months long and end on April 30 and October 31 of each year. The first purchase period to the Company's employees to purchase shares under the ESPP began on November 1, 2022. Each employee who is a participant in the ESPP may purchase shares by authorizing contributions at a minimum of 1% up to a maximum of 10% of his or her compensation for each pay period, to a maximum of $15 per purchase period and $25 per year, which will then be used to purchase shares on the last business day of the purchase period at a price equal to 85% of the fair market value of common stock on the offering date or the exercise date whichever is less. During the year ended December 31, 2022, no shares were purchased under the ESPP. As of December 31, 2022, the Company has withheld $188 of contributions from its employees. A summary of stock option activity related to the Plans as of December 31, 2022 is as follows: Outstanding Stock Options Weighted Average Exercise Price Weighted Average Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2021 29,238,432 $ 0.48 7.35 $ 127,345 Granted — — Exercised (3,219,957) 0.36 Forfeited (569,123) 0.60 Expired (55,812) 0.17 Repurchased — — Balance at December 31, 2022 25,393,540 $ 0.49 6.45 $ 2,277 Vested and expected to vest as of December 31, 2022 25,393,540 $ 0.49 6.45 $ 2,277 Vested and exercisable as of December 31, 2022 20,356,221 $ 0.47 6.14 $ 2,277 The aggregate intrinsic value is the difference between the current fair value of the underlying common stock and the exercise price for in-the-money stock options. The Company did not grant any options during the years ended December 31, 2022 and 2021. The following table summarizes the RSU award activity under the Plans: Shares Weighted Average Grant date Fair Value per Share Unvested at December 31, 2021 7,434,743 $ 5.80 Granted 11,719,867 3.49 Forfeited (2,475,483) 4.37 Vested (3,908,031) 4.99 Unvested at December 31, 2022 12,771,096 $ 4.00 The total fair value of RSUs that vested during the year ended December 31, 2022 was $10,992. Stock-Based Compensation Expense —The following table summarizes stock-based compensation expense recorded in each component of operating expenses in the Company’s consolidated statements of operations and comprehensive loss for the year ended December 31, 2022 and 2021 (in thousands): Twelve months ended December 31, 2022 2021 Research and development $ 7,201 $ 2,175 Sales and marketing 4,696 1,381 General and administrative 11,931 6,462 Cost of revenue 131 — Total stock-based compensation $ 23,959 $ 10,018 As of December 31, 2022, the Company had $5,418 of unrecognized compensation expense for related stock option grants. This cost is expected to be recognized over an estimated weighted average period of 1.35 years. The total unrecognized compensation expense for RSUs was $47,007 as of December 31, 2022 which is expected to be recognized over an estimated weighted average period of 2.44 years. The total unrecognized compensation expense for the ESPP was $1,152 as of December 31, 2022 which is expected to be recognized over an estimated weighted average period of 1.83 years. The Company uses the Black-Scholes option-pricing model to estimate the grant-date fair value of ESPP purchase rights, which requires the input of subjective assumptions such as expected term, expected stock price volatility, risk-free interest rate and dividend yield as discussed below. The fair value of each of the four purchase periods is estimated separately. Expected Term —The expected term for ESPP is the length of time from the grant date to the date on which the stock is purchased by the employees. Expected Volatility —Expected volatility is estimated using a combination of the average historical volatility of the Company's own stock and those of comparable companies’ stock. Risk-Free Interest Rate —The risk-free interest rates are based on US Treasury yields in effect at the grant date for notes with comparable terms as the awards. Dividend Yield —The expected dividend-yield assumption is based on the Company’s current expectations about its anticipated dividend policy. The following table summarizes the range of valuation assumptions used in estimated the fair value of the ESPP during the period: Year Ended December 31, 2022 Expected term (years) 0.5 - 2 Expected volatility 94.8% - 105.3% Risk-free interest rate 4.5% - 4.8% Dividend yield — %

Revenue

Revenue	12 Months Ended
Revenue	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE Sale of Prototypes The Company recorded revenue for prototype sales of $1,743 and $1,004 in 2022 and 2021 respectively. The Company does not incur significant contract costs in fulfilling or obtaining their contracts with customers. Development Contracts The Company has entered into research and development contracts with companies primarily in the automotive industry. The Company assessed the number of performance obligations associated with the promises under each agreement, primarily the delivery of customized 4Sight TM perception-related goods and services, and recognized $1,904 and $2,003 in revenue for performance obligations satisfied during years ended 2022 and 2021 respectively, in the consolidated statements of operations and comprehensive loss. Disaggregation of Revenue The Company recognized the following revenues by geographic area based on the primary billing address of the customer and by the timing of the transfer of goods or services to customers (point in time or over time), as it believes such criteria best depict how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Total revenue based on the disaggregation criteria described above are as follows (in thousands): Twelve months ended December 31, 2022 2021 Revenue by primary geographical market: United States $ 2,471 $ 2,215 Germany 65 536 Europe 855 111 Asia 256 145 Total $ 3,647 $ 3,007 Revenue by timing of recognition: Recognized at a point in time $ 1,982 $ 2,991 Recognized over time 1,665 16 Total $ 3,647 $ 3,007 Contract Liabilities Contract liabilities consisted of the following as of December 31, 2022 and 2021 (in thousands): As of December 31, 2022 2021 Contract liabilities, current $ 987 $ 2,287 Contract liabilities, noncurrent — 631 Total $ 987 $ 2,918 Contract liabilities, noncurrent are included in other noncurrent liabilities on the consolidated balance sheet. The following table shows the significant changes in contract liabilities balance as of December 31, 2022 and 2021 (in thousands): Twelve months ended December 31, 2022 2021 Beginning balance $ 2,918 $ 660 Revenue recognized that was included in the contract liabilities beginning balance (1,931) (570) Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period — 2,828 Ending balance $ 987 $ 2,918 Remaining Performance Obligations Revenue allocated to remaining performance obligations represents the transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied. It includes unearned revenue and amounts that will be invoiced and recognized as revenue in future periods and does not include contracts where the customer is not committed. The customer is not considered committed where they are able to terminate for convenience without payment of a substantive penalty under the contract. Additionally, as a practical expedient, the Company has not disclosed the value of unsatisfied performance obligations for contracts with an original expected length of one year

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plan	EMPLOYEE BENEFIT PLANEmployees of the Company may participate in the AEYE, Inc. 401(k) Plan (the "401(k) Plan"), a defined contribution plan, which qualifies under Section 401(k) of the Internal Revenue Code. Participating employees may contribute into a traditional plan with pretax salary or into a Roth plan with after tax salary up to statutory limits. In 2022, the 401(k) Plan provides for Company safe harbor matching contributions of 100% of the employee contribution, up to 5% of each employee's earnings, which vest upon the first day of employment. In 2021, the 401(k) Plan provided for Company safe harbor matching contributions of 100% of the first 3% of employee earnings, and 50% of the next 2% of earnings. The Company made contributions of $1,177 and $565 for the years ended December 31, 2022 and 2021, respectively.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES For the years ended December 31, 2022 and 2021, the Company recognized $58 and $0 provision for income taxes, respectively. The provision for the year ended December 31, 2022 was comprised of $9 and $49 in state and foreign taxes, respectively. Utilization of net operating loss carryforwards, tax credits, and other attributes may be subject to future annual limitations due to the ownership change limitations provided by Section 382 of the Internal Revenue Code and similar state provisions. The following table presents a reconciliation of the federal statutory rate of 21.0% to our effective tax rate for the periods presented: Twelve months ended December 31, 2022 2021 U.S. federal tax benefit at statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 0.0 % 11.8 % Non-deductible expenses and other (1.0) % (0.3) % Stock-based compensation (2.3) % (1.1) % Research and development credits 3.5 % 1.2 % Transaction Cost 0.0 % 3.9 % Foreign rate differential (4.1) % (3.1) % Change in valuation allowance, net (17.2) % (33.4) % Effective tax rate (0.1) % 0.0 % For 2022 and 2021, our effective tax rate differs from the amount computed by applying the statutory federal and state income tax rates to net loss before income tax, primarily as the result of state income taxes, R&D credits and changes in our valuation allowance. Significant components of the Company’s deferred tax assets as of December 31, 2022 and December 31, 2021 are presented below: As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 49,669 $ 41,856 Research and development credit carryforward 7,967 4,545 Stock-based compensation 1,048 1,040 Property and equipment 234 178 Operating lease liabilities 4,435 — Section 174 R&D capitalization 9,053 — Other accruals 630 734 Gross deferred tax assets 73,036 48,353 Valuation allowance (68,868) (48,353) Deferred tax assets net of valuation allowance 4,168 — Deferred tax liabilities: Right-of-use assets (4,168) — Gross deferred tax liabilities (4,168) — Total deferred tax assets (liabilities)—net $ — $ — Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. The Company could not conclude that it was more likely than not that tax benefits from operating losses would be realized, and accordingly, has provided a full valuation allowance against its net deferred tax assets. The valuation allowance as of December 31, 2022 was $68,868 which increased from $48,353 at December 31, 2021. The increase in the valuation allowance is primarily due to additional reserve required against net operating losses and research credits generated during the year ended December 31, 2022. The Company has not provided deferred taxes on unremitted earnings attributable to foreign subsidiaries because these earnings are intended to be reinvested indefinitely. No deferred tax asset was recognized since the Company does not believe the deferred tax asset will be realized in the foreseeable future. The accumulated foreign earnings of the Company's foreign subsidiaries totaled $111 as of December 31, 2022. If the Company's foreign earnings were repatriated, additional tax expense might result. The Company determined that the calculation of the amount of unrecognized deferred tax liability related to these cumulative unremitted earnings attributable to foreign subsidiaries is not practicable. As of December 31, 2022, the Company had $184,007 and $127,624 of federal and state net operating losses available to reduce future taxable income, respectively, of which $12,256 will begin to expire in 2033 for federal tax purposes and $5,033 will begin to expire in 2029 for state tax purposes. Approximately $171,751 of federal net operating loss included above can be carried forward indefinitely. As of December 31, 2021, the Company had $156,584 and $104,555 of federal and state net operating losses available to reduce future taxable income, which will begin to expire on 2033 for federal and 2035 for state tax purposes. The Company also has federal and state research and development tax credit carryforwards of $6,193 and $4,597 as of December 31, 2022 and $3,373 and $2,854 as of December 31, 2021. The federal credits begin to expire in 2034 and the state credits have no expiration date. The Company has completed a Section 382 study through December 31, 2021 to determine whether it had experienced a change in ownership and, if so, whether the tax attributes (NOL and credits) were impaired. As a result of this study, the Company concluded all of its NOLs and credits would be available to use as of December 31, 2021. However future change in ownership may limit the ability to use tax attributes under Section 382. Under Section 382 of the Internal Revenue Code of 1986, as amended, the Company’s ability to utilize NOL or other tax attributes, such as research tax credits, in any taxable year, may be limited if the Company has experienced an “ownership change.” Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock within a specific testing period. Similar rules may apply under state tax laws. Unrecognized Tax Benefits —The following is a tabular reconciliation of the total amounts of unrecognized tax benefits: Twelve months ended December 31, 2022 2021 Unrecognized tax benefits as of the beginning of the year $ 1,681 $ 1,210 Increases related to prior year tax provisions 182 40 Increase related to current year tax provisions 959 431 Unrecognized tax benefits as of the end of the year $ 2,822 $ 1,681 The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. As of December 31, 2022 and December 31, 2021 there was no accrued interest nor penalties related to uncertain tax positions. The Company reports income taxes in accordance with ASC 740, which requires an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred tax amounts are determined by using the enacted tax rates expected to be in effect when the temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company has a history of operating losses and has incurred cumulative book losses since its formation. Based upon the history of losses, the Company has determined that it is more likely than not that the net deferred tax assets will not be realized, and accordingly, a full valuation allowance has been recorded. The Company files income tax returns in the U.S., various state jurisdictions, and foreign jurisdictions. The U.S., state and foreign jurisdictions have statutes of limitations that generally range from three to five years. Due to the Company’s net losses, substantially all of its federal, state and local income tax returns are subject to examination for federal and state purposes since inception. The Company is not currently under examination for federal or state income tax purposes. Effective for tax years beginning on or after January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017, companies are required to capitalize Internal Revenue Code ("IRC") Section 174 research and experimental expenses paid or incurred during the year. These expenses are amortized over 5 years for research and development performed in the United States and over 15 years for expenses related to research and development performed outside of the United States. As a result of the IRC Section 174 research and development capitalization, the Company recognized a deferred tax asset for the future tax benefit of the amortization deductions.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
Commitment and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Matters —The Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will have a material effect on the financial position, results of operations, or cash flows of the Company.

Related Parties

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Parties	RELATED PARTIESSince November 2016, the Company has employed a sibling of Mr. Dussan, the Company’s Chief Technology Officer, who held the position of Director, Human Resources and Sr. Manager of Human Resources at December 31, 2022 and 2021, respectively. For the years ended December 31, 2022 and 2021, Mr. Dussan’s sibling received total cash compensation of $162 and $136, respectively. For the years ended December 31, 2022 and 2021, Mr. Dussan’s sibling was granted 22,500 and 1,860 RSUs, respectively. In addition, he participates in all other benefits that the Company generally offers to all of its employees.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS Management has evaluated subsequent events through March 15, 2023 and determined that there were no such events requiring recognition or disclosure in the financial statements other than the below. DGCL 205 Petition On August 12, 2021, CF Finance Acquisition Corp. III, or the Pre-Merger Company, our predecessor, held a special meeting of stockholders to approve certain matters related to the business combination between the Pre-Merger Company and AEye Technologies, Inc. Among the proposals presented to the Pre-Merger Company stockholders were proposals to (i) adopt a certificate of amendment to the Pre-Merger Company’s amended and restated certificate of incorporation to increase the number of authorized shares of its Class A Common Stock from 200,000,000 to 300,000,000, or the Authorized Share Amendment, and (ii) amend and restate the charter in connection with the business combination, which included eliminating its Class B Common Stock immediately prior to the closing of the business combination after giving effect to the conversion of each outstanding share of Class B Common Stock into one share of its Class A Common Stock, or the Class B Elimination Amendment. The proposals each received approval from the holders of a majority of the Pre-Merger Company’s outstanding shares of Class A Common Stock and Class B Common Stock, voting together as a single class, that were outstanding as of the record date for such special meeting. Following the special meeting, the business combination was closed and the Pre-Merger Company changed its name to "AEye, Inc." A recent ruling by the Court of Chancery of the State of Delaware, or Chancery Court, introduced uncertainty as to whether Section 242(b)(2) of the General Corporation Law of the State of Delaware, or DGCL, would have required the Authorized Share Amendment to be approved by a separate vote of the majority of the Pre-Merger Company’s then-outstanding shares of Class A Common Stock and the Class B Elimination Amendment to be approved by a separate vote of the majority of the Pre-Merger Company’s then-outstanding shares of Class B Common Stock. Although we received no demands or inquiries from our stockholders regarding the potential uncertainty surrounding our Second Amended and Restated Certificate of Incorporation, or our Charter, which was adopted at the special meeting, and our own analysis determined that a separate class vote to adopt the Charter was not necessary, in light of the recent Chancery Court decision, and to resolve any potential uncertainty with respect to our Charter, or our capital structure, on February 23, 2023, we filed a petition in the Chancery Court under Section 205 of the DGCL, our Section 205 Petition, to seek validation of the Authorized Share Amendment, our Charter, and the shares we issued in reliance thereon. Section 205 permits the Chancery Court, in its discretion, to validate potentially defective corporate acts after considering a variety of factors. Concurrently with the filing of our Section 205 Petition, we filed a motion to expedite the hearing, which was granted. The hearing was set for March 14, 2023. At the March 14, 2023 hearing on our Section 205 Petition, no objections were filed and the court granted our petition. The court order declared our Charter to be valid and effective as of the date and time it was originally filed and that all shares of our capital stock that we have issued in reliance on our Charter were valid as of the date such shares were issued, thereby eliminating any uncertainty with respect to our Charter or any shares we have issued or may issue in the future in reliance thereon. Silicon Valley Bank Closure On March 10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or FDIC, was appointed as receiver. We have deposit accounts at SVB. The standard deposit insurance amount is up to $250 per depositor, per insured bank, for each account ownership category. As of March 10, 2023, we had approximately $9,600 in deposit accounts at SVB, of which $2,150 was held as collateral for letters of credit under our lease agreement. We do not maintain any other material accounts or lines of credit with SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023. We began the process of withdrawing our deposits from SVB on March 13, 2023.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principle of Consolidation	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Certain prior year amounts have been reclassified for consistency with the current year presentation. Advances to suppliers has been broken out from Other within Footnote 6, Prepaid and other current assets. Amortization of premiums on marketable securities, net within Footnote 13, Interest Expense and Other is now presented as Amortization of premiums on marketable securities, net of accretion and discounts.
Use of Estimates	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include investments, fair value of the 2022 convertible note, embedded derivative and warrant liabilities, and stock-based compensation.
Segment Reporting	The Company manages its business on the basis of one reportable and operating segment. Operating segments are defined as components of an enterprise with separate financial information, and are evaluated regularly by the chief operating decision maker, which is the Company's Chief Executive Officer (“CEO”). The CEO decides how to allocate resources and assesses the Company’s performance based upon consolidated financial information. All of the Company's sales were made to customers (in USD) located in the U.S., Europe, and Asia through AEye, Inc.
Cash, Cash Equivalents	The Company considers all highly liquid investments, such as treasury bills, commercial paper, certificates of deposit, and money market instruments with maturities of three months or less at the time of acquisition to be cash equivalents. Cash equivalents primarily consist of amounts held in interest-bearing money market accounts that are readily convertible to cash. Cash equivalents are stated at cost, which approximates fair market value.
Marketable Securities	Marketable securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses in fair value of the available-for-sale (“AFS”) debt securities are reported in other comprehensive income (loss). When the AFS debt securities are sold, cost is based on the specific identification method, and the realized gains and losses are included in other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company considers all AFS debt securities as available for use to support current operations, including those with maturity dates beyond one year and are classified as current assets under marketable securities in the accompanying consolidated balance sheets. AFS debt securities included in marketable securities on the consolidated balance sheets consist of securities with original maturities greater than three months at the time of purchase. Interest on marketable securities is included within interest income.
Restricted Cash	The Company determines current or non-current classification of restricted cash based on the expected duration of the restriction.
Concentration of Credit Risk	Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities, and accounts receivable. The Company places its cash and cash equivalents with major financial institutions, which management assesses to be of high credit quality, to limit the exposure of each investment. The Company’s marketable securities have investment grade ratings when purchased which mitigates risk. The Company’s accounts receivables are derived from customers located in the U.S., Europe, and Asia. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions. The Company generally does not require collateral.
Fair Value of Financial Instruments	The Company defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.
Derivatives	The Company accounts for derivative instruments in accordance with Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) Topic 815, Derivatives and Hedging (“ASC 815”). The Company’s objectives and strategies for using derivative instruments, and how the derivative instruments and related hedged items are accounted for affect the financial statements. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk. Terms of convertible debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value.
Accounts Receivable, net	Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. If necessary, accounts receivable are reduced by an allowance for doubtful accounts, which is the Company’s best estimate of the amount of credit losses inherent in its existing accounts receivable. The Company reviews the need for an allowance for doubtful accounts quarterly based on historical experience with each customer and the specifics of each arrangement.
Inventories, net	Inventories consist of raw materials, work in progress, and finished goods. Inventories are stated at the lower of cost and net realizable value and costs are computed under the standard cost method. Inventories that are not expected to be consumed in the next 12 months are classified within Other noncurrent assets. Prototype inventory cost consists of the associated raw material, direct labor, indirect labor and other overhead costs. The Company evaluates the need for inventory write-downs associated with obsolete, slow moving, and non-sellable inventory by reviewing estimated net realizable values on a periodic basis and records a provision for excess and obsolete inventory to adjust the carrying value of inventory as needed.
Deferred Transaction Costs	The Company capitalized qualified legal, accounting, and other direct costs related to the Business Combination which were deferred until completion of the Business Combination. In August 2021, upon the completion of the Business Combination, all deferred costs were offset against proceeds from the Business Combination and the private investment in public equity (“PIPE”) financing.
Property and Equipment, net	Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 2 to7 years. Leasehold improvements are amortized over the shorter of the lease term or expected useful life of the improvements. Construction in progress is the construction or development of property and equipment that have not yet been placed in service. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.
Impairment of Long-Lived Assets	The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Warrant Liability	The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance. The warrants assumed in connection with the 2022 convertible note are accounted for in accordance with ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, under which the warrants do not meet the criteria for equity treatment and must be recorded as liabilities. The Private Placement Warrants issued in connection with the IPO are classified as liabilities. The Company adjusts the warrants to fair value at each reporting period. The warrant liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the consolidated statements of operations
Leases	The Company determines if an arrangement is or contains a lease at inception. The Company evaluates the classification of leases at commencement, and, as necessary, at modification. Operating leases, consisting of office leases, are included in Right-of-use ("ROU") assets, Accrued expenses and other current liabilities
Convertible Notes	The Company elected to early adopt Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The Company has elected to apply the fair value measurement option to the 2022 convertible note on the date that the Company first recognized the convertible note on September 15, 2022. The Company acknowledges that its election to apply the fair value option is irrevocable. The Company recognized costs incurred upon issuance of the 2022 convertible note as an expense in its consolidated income statement for the twelve months ended December 31, 2022. The 2022 convertible note is classified and presented as a current liability on the Consolidated Balance Sheet as of December 31, 2022. Changes in fair value are recorded in the consolidated statements of operations and changes in fair value related to credit risk are recorded in other comprehensive loss. The Company reports interest expense, including accrued interest, related to this convertible debt under the fair value option, within the change in fair value of convertible notes in the consolidated statement of operations.
Revenue Recognition and Cost of Revenue	The Company generates revenues from the sale of prototypes and from development arrangements with automakers and suppliers to automakers. Under FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company accounts for such arrangements as contracts with customers and accordingly recognizes revenue by applying the following steps: • Identification of the contract, or contracts, with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations in the contract • Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue from the sale of prototypes is generally recognized at a point in time when control of the goods is transferred. Certain prototype sales contracts include services to install and commission or customize the prototypes for customers. Revenues from these services are categorized as prototype revenue and recognized either over time as the services are being performed, or at a point in time, depending on the nature of the services and whether the criteria for recording revenue over time are met in accordance with ASC 606. Revenue from development arrangements is either recognized at a point in time or over time depending on the performance obligations in the contract. For performance obligations that are satisfied over time, such as services which require engineering and development based on customer requirements, the Company recognizes revenue using an input method based on contract costs incurred to date compared to total estimated contract costs. See Note 18, Revenue, for additional information related to the application of ASC 606 to the Company’s primary revenue streams. Sales taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from revenues in the consolidated statements of operations and comprehensive loss. When a contract involves multiple performance obligations, the Company accounts for individual products and services separately if the customer can benefit from the product or service on its own or with other resources that are readily available to the customer and the product or service is separately identifiable from other promises in the arrangement. The consideration is allocated between separate performance obligations in proportion to their estimated standalone selling price (SSP). The SSP reflects the price the Company would charge for a specific product or service if it were sold separately in similar circumstances and to similar customers. If the selling price is not directly observable, the Company determines SSP using information that may include other observable inputs, such as the cost plus margin approach, to estimate SSP. In instances where SSP is not directly observable, the Company determines SSP using information that may include other observable inputs such as expected costs plus margin, or uses the residual approach for performance obligations whose SSP is highly variable or uncertain. The Company provides standard product warranties for a term of typically one year to ensure that its products comply with agreed-upon specifications. Standard warranties are considered to be assurance type warranties and are not accounted for as separate performance obligations. Estimated future warranty costs are accrued and charged to cost of sales in the period that the related revenue is recognized. These estimates are based on historical warranty experience and any known or expected changes in warranty exposure, such as trends of product reliability and costs of repairing and replacing defective products. The Company assesses the adequacy of its recorded warranty liabilities on a quarterly basis and adjusts the amounts as necessary. Warranty costs are included within accrued expenses and other liabilities on the consolidated balance sheets. Refer to Note 10 for further information on warranty reserve amounts. Contract assets and liabilities. Contract assets primarily represent revenues recognized for performance obligations that have been satisfied but for which amounts have not been billed. The Company did not have any contract assets as of December 31, 2022. Contract liabilities relate to deferred revenue. Deferred revenue consists of amounts that have been invoiced and/or cash received but for which revenue has not been earned. This generally includes unrecognized revenue balances for development arrangements. Deferred revenue that will be realized during the succeeding 12-month period is recorded within current liabilities and the remaining deferred revenue is recorded as noncurrent liabilities. Right of return. The Company’s general terms and conditions for its contracts do not contain a right of return that allows the customer to return products and receive a credit. Therefore, the Company does not estimate returns and generally recognizes revenue at contract price upon product shipment or delivery. Significant financing component. In certain arrangements, the Company receives payment from a customer either before or after the performance obligation has been satisfied. The expected timing difference between the payment and satisfaction of performance obligations for all of the Company’s contracts is one year or less; therefore, the Company applies a practical expedient and does not consider the effects of the time value of money on transaction price. The Company’s contracts with customer prepayment terms do not include a significant financing component because the primary purpose is not to receive financing from the customers. Contract modifications. The Company may modify contracts to offer customers additional products or services. Each of the additional products and services are generally considered distinct from those products or services transferred to the customer before the modification. The Company evaluates whether the contract price for the additional products and services reflects the standalone selling price as adjusted for facts and circumstances applicable to that contract. In these cases, the Company accounts for the additional products or services as a separate contract. In other cases where the pricing in the modification does not reflect the standalone selling price as adjusted for facts and circumstances applicable to that contract, the Company accounts for the additional products or services as part of the existing contract primarily on a prospective basis. Judgments and estimates. Accounting for contracts recognized over time under ASC 606 involves the use of various techniques to estimate total contract revenue and costs. Due to uncertainties inherent in the estimation process, it is possible that estimates of costs to complete a contract will be revised in the near-term. The Company reviews and updates its contract-related estimates quarterly, and records adjustments as needed. For those performance obligations for which revenue is recognized using a cost-to-cost input method, changes in total estimated costs, and related progress towards complete satisfaction of the performance obligation, are recognized in the period in which the revisions to the estimates are made.
Research and Development Expenses	Research and development expenses include personnel costs (including salaries, benefits, bonuses, and stock-based compensation), new hardware and software materials to the extent no future economic benefits are expected, other related expenses such as lab equipment, third party development-related contractors, and allocated overhead expenses. Substantially all the R&D expenses are related to the development of new products and services, including contract development expenses. They are expensed as incurred and included in the consolidated statements of operation and comprehensive loss.
Stock-Based Compensation	The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based awards based on estimated grant-date fair values. The Company uses the straight-line attribution method to allocate compensation cost to reporting periods over each awardee’s requisite service period, which is generally the vesting period of the award. The Company measures nonemployee awards at the date of grant, which generally is the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The Company’s policy is to recognize the effect of forfeitures in the period they occur. The grant-date fair value of the restricted stock units, or “RSUs,” is equal to the fair market value of the Company’s common stock on the grant date. The grant-date fair value for stock options and stock purchase rights under the employee stock purchase plan ("ESPP") is estimated using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of subjective assumptions, including the option’s expected term and the price volatility of the underlying stock. Stock options and RSUs for all periods prior to the Business Combination have been retroactively restated to give effect to the recapitalization.
Income Taxes	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of their net recorded amount, an adjustment to the deferred tax asset valuation allowance would be made to reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”) on the basis of a two-step process in which determinations are made (1) whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.
Net Loss per Share	Basic net loss per share is computed using net loss available to common stockholders divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the dilutive effects of stock options, restricted stock units, preferred stock, stock to be issued under the ESPP, convertible notes, and warrants outstanding during the period to the extent such securities would not be anti-dilutive and is determined using the if-converted and treasury stock methods. The Company calculates weighted average number of common shares outstanding during the period using the Company’s Class A common stock outstanding. As the merger has been accounted for as a reverse capitalization, the consolidated financial statements of the merged entity reflects the continuation of the pre-merger AEye Technologies financial statements, which has been retroactively adjusted to the earliest period presented to reflect the legal capital of the legal acquirer, CF III. As a result, net loss per share was also restated for periods ended prior to the Business Combination. See Note 2 for details on this recapitalization and Note 16 for the retroactive restatement of net loss per share.
Comprehensive Loss	Comprehensive loss includes all changes in equity (net assets) from non-owner sources during a period, changes in fair value due to instrument-specific credit risk, and net unrealized gains (losses) on available-for-sale debt securities.
Recently Accounting Pronouncements and Recently Adopted Accounting Guidance	In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments , which has subsequently been amended by ASU No. 2018-19, ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, and ASU No. 2019-11. The objective of the guidance in ASU 2016-13 is to allow entities to recognize estimated credit losses in the period that the change in valuation occurs. ASU 2016-13 requires an entity to present financial assets measured on an amortized cost basis on the balance sheet net of an allowance for credit losses. Available-for-sale and held to maturity debt securities are also required to be held net of an allowance for credit losses. For public business entities, this standard is effective for fiscal years beginning after December 15, 2019. For smaller reporting companies, the standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures and will adopt the guidance on January 1, 2023 as permitted for smaller reporting companies. In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02. FASB ASC Topic 842, Leases (“ASC 842”) supersedes the previous accounting guidance for leases included within ASC 840. The new guidance generally requires an entity to recognize operating and financing lease liabilities and corresponding right-of-use assets on its balance sheet, as well as recognize the associated lease expenses on its statements of operations in a manner similar to that required under current accounting rules. The guidance requires a modified retrospective transition approach with application in all comparative periods presented (the “Comparative Method”), or alternatively, as of the effective date as the date of initial application without restating comparative period financial statements (the “Effective Date Method”). The Company adopted the new standard on January 1, 2022 using the Effective Date Method. Upon adoption, the Company recorded net ROU assets and lease liabilities totaling approximately $16,284 and $19,921, respectively, and a reversal of deferred rent of $3,032; there were no cumulative effect adjustments as of January 1, 2022. The standard did not have a material effect on the Company's consolidated statements of operations and comprehensive loss and the consolidated statement of cash flows. The Company elected the transition practical expedient package which, among other things, allows the carryforward of historical lease classifications. The Company will continue to apply Topic 840 prior to January 1, 2022, including Topic 840 disclosure requirements, in the comparative periods presented. The company did not elect to apply the hindsight practical expedient, which permits entities to use hindsight in determining the lease term and assessing impairment of right-of-use assets. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This standard simplifies the accounting for income taxes by, among other things, eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2021. The Company adopted ASU 2019-12 as of January 1, 2022, and the Company's adoption did not have a material impact on the consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue from Major Customers Representing 10% or More of Total Revenue	For the years ended December 31, 2022 and 2021, revenue from the Company’s major customers representing 10% or more of total revenue was as follows: Twelve months ended December 31, 2022 2021 Customer A 51 % 55 % Customer B 13 % * Customer C 10 % * *Customer accounted for less than 10% of total revenue in the period.

Recapitalization (Tables)

Recapitalization (Tables)	12 Months Ended
Recapitalization (Tables)	Dec. 31, 2022
Reverse Recapitalization [Abstract]
Schedule of Reverse Recapitalization	The following table reconciles the elements of the Business Combination to the consolidated statements of cash flows and the consolidated statements of changes in stockholders’ deficit for period ended December 31, 2021 (in thousands, except share data): Cash - CF III's trust and cash (net of redemption) $ 36,811 Cash - Private offering 220,000 Less: transaction costs and advisory fees paid (52,661) Net Business Combination and private offering $ 204,150 The number of shares of common stock issued immediately following the closing of the Business Combination were: CF III Class A common stock, outstanding prior to Business Combination 23,000,000 Less: redemption of CF III Class A common stock 19,355,365 Class A common stock of CF III 3,644,635 CF III founder shares 5,750,000 CF III Private Placement shares 500,000 CF III Shares issued in PIPE 22,000,000 Business Combination and PIPE shares 31,894,635 Legacy AEye shares 122,509,667 August 16, 2021 154,404,302 The number of Legacy AEye shares was determined as follows: AEye shares AEye shares, effected for Exchange Ratio Balance at December 31, 2019 11,283,838 41,984,908 Recapitalization applied to Convertible preferred stock outstanding at December 31, 2019 16,383,725 60,960,574 Exercise of common stock options - 2020 504,524 1,877,233 Repurchase of common stock - 2020 (950,352) (3,536,070) Exercise of common stock options - 2021 (pre-Closing) 54,859 204,119 Conversion of Convertible Notes and Accrued Interest – 2021 5,584,308 20,778,097 Exercise of common stock and Series A preferred stock warrants - 2021 64,719 240,806 Total 122,509,667 August 16, 2021 (Closing) Preferred stock shares Exchange ratio Common stock shares Series A Convertible preferred stock (pre-combination) 9,226,734 3.7208 34,330,838 Series B Convertible preferred stock (pre-combination) 7,156,991 3.7208 26,629,736 Total 16,383,725 60,960,574

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The Company’s financial assets and liabilities measured at fair value on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): Fair Value Measured as of December 31, 2022 Using: Adjusted Cost Unrealized losses Fair Value Cash and Cash Equivalent Marketable Securities Assets Level 1 Money market funds $ 14,253 $ — $ 14,253 $ 14,253 $ — Level 2 Asset-backed securities $ 3,507 $ (119) $ 3,388 $ — $ 3,388 Corporate bonds 22,139 (240) 21,899 — 21,899 Commercial paper 20,760 — 20,760 — 20,760 U.S. Government securities 29,983 (895) 29,088 — 29,088 Total financial assets $ 90,642 $ (1,254) $ 89,388 $ 14,253 $ 75,135 Liabilities Level 2 Private placement warrant liability $ — $ — $ 7 $ — $ — Level 3 Convertible notes — — 8,594 — — Derivative warrant liability — — 119 — — Total financial liabilities $ — $ — $ 9,200 $ — $ — Fair Value Measured as of December 31, 2021 Using: Adjusted Cost Unrealized losses Fair Value Cash and Cash Equivalent Marketable Securities Assets Level 1 Money market funds $ 4,863 $ — $ 4,863 $ 4,863 $ — Level 2 Asset-backed securities $ 26,491 $ (68) $ 26,423 $ — $ 26,423 Corporate bonds 48,643 (150) 48,493 — 48,493 Commercial paper 45,145 — 45,145 — 45,145 U.S. Government securities 29,936 (173) 29,763 — 29,763 Total financial assets $ 155,078 $ (391) $ 154,687 $ 4,863 $ 149,824 Liabilities Level 2 Private placement warrant liability $ — $ — $ 155 $ — $ — Total financial liabilities $ — $ — $ 155 $ — $ —
Schedule of the Changes in Fair Value of Level 3 Financial Instruments	The following table presents a summary of the changes in fair value of the Company’s Level 3 financial instruments for the year ended December 31, 2022: 2022 Convertible Note Derivative Warrant Liability Total Balance at December 31, 2021 $ — $ — $ — Additions 9,512 488 10,000 Payments or conversions (1,474) — (1,474) Change in fair value included in other income (expense) 531 (369) 162 Change in fair value due to instrument specific credit risk included in other comprehensive income 25 — 25 Balance at December 31, 2022 $ 8,594 $ 119 $ 8,713
Schedule of Key Inputs into the Black-Sholes Option Pricing Model	The key inputs into the binomial-lattice model for the convertible note valued at December 31, 2022 are as follows: December 31, 2022 Remaining term (years) 1.2 Expected volatility 90.4 % Risk-free interest rate 4.6 % Dividend yield — % Estimated credit spread 37.7 % The key inputs into the Monte-Carlo simulation model for the derivative warrant liability valued at December 31, 2022 are as follows: December 31, 2022 Expected term (years) 3.7 Expected volatility 90.4 % Risk-free interest rate 4.1 % Dividend yield — % Exercise price $ 3.50

Cash, Cash Equivalents, and R_2

Cash, Cash Equivalents, and Restricted Cash (Tables)	12 Months Ended
Cash, Cash Equivalents, and Restricted Cash (Tables)	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	Cash, cash equivalents (which consists entirely of money market funds) and restricted cash as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Cash and cash equivalents $ 19,064 $ 14,183 Restricted cash 2,150 2,150 Total cash, cash equivalents, and restricted cash $ 21,214 $ 16,333
Schedule of Restricted Cash	Cash, cash equivalents (which consists entirely of money market funds) and restricted cash as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Cash and cash equivalents $ 19,064 $ 14,183 Restricted cash 2,150 2,150 Total cash, cash equivalents, and restricted cash $ 21,214 $ 16,333

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Net of Write-Downs	Inventory, net of write-downs, as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Raw materials $ 2,022 $ 1,544 Work in-process 2,484 2,447 Finished goods 47 94 Total inventory, net $ 4,553 $ 4,085

Prepaid and Other Current Ass_2

Prepaid and Other Current Assets (Tables)	12 Months Ended
Prepaid and Other Current Assets (Tables)	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Prepaid expenses $ 4,203 $ 3,980 Demonstration units 281 224 Advances to suppliers 984 745 Other 713 102 Total prepaid and other current assets $ 6,181 $ 5,051

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2022
Leases [Abstract]
Schedule of Operating Lease Expenses and Supplemental Cash Flow Information	The components of operating lease expenses for the twelve months ended December 31, 2022 were as follows (in thousands): Twelve months ended December 31, 2022 Operating lease cost $ 2,382 Variable lease cost 241 Total operating lease cost $ 2,623 Supplemental cash flow information for the twelve months ended December 31, 2022 were as follows (in thousands): December 31, 2022 Cash paid for operating leases included in operating cash flows $ (1,341)
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to operating leases was as follows (in thousands): December 31, 2022 Operating lease right-of-use assets $ 15,502 Operating lease liabilities: Operating lease liabilities, current $ 2,455 Operating lease liabilities, non-current 16,681 Total operating lease liabilities $ 19,136 December 31, 2022 Weighted average remaining lease term (in years) 9.26 Weighted average discount rate 5.35 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities were as follows (in thousands). Years ended - December 31: 2023 $ 2,516 2024 2,570 2025 2,583 2026 2,660 2027 2,701 Thereafter 11,116 Total lease payments 24,146 Less amount to discount to present value (5,010) Present value of lease liabilities $ 19,136
Schedule of Future Minimum Payments Under Noncancellable Operating Leases under ASC 840	Future minimum payments as of December 31, 2021 under the noncancellable operating leases are as follows (in thousands): Operating Leases Years ended: 2022 2,393 2023 2,341 2024 2,412 2025 2,484 2026 and after 2,340 Total minimum lease payments 11,970

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net as of December 31, 2022 and 2021 consists of the following (in thousands): As of December 31, 2022 2021 Machinery and equipment $ 2,528 $ 1,444 Computers, software and related equipment 432 268 Office furniture and equipment 651 341 Vehicles 846 342 Leasehold improvements 4,830 4,725 Construction in progress 1,401 213 Total property and equipment 10,688 7,333 Less accumulated depreciation and amortization (3,023) (2,204) Property and equipment, net $ 7,665 $ 5,129

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	12 Months Ended
Other Noncurrent Assets (Tables)	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Noncurrent Assets	Other noncurrent assets as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Non-current inventory $ 1,491 $ — Long-term prepaid expenses 901 1,376 Security deposits 81 133 Total other noncurrent assets $ 2,473 $ 1,509

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities as of December 31, 2022 and 2021 were as follows (in thousands): As of December 31, 2022 2021 Accrued purchases and other $ 4,092 $ 1,947 Operating lease liabilities - current 2,455 — Accrued bonuses 1,022 3,408 Accrued payroll 1,148 957 Accrued payroll taxes 526 1,547 Warranty reserve 480 275 Income tax payable 41 — Deferred rent - current — 605 Total accrued expenses and other current liabilities $ 9,764 $ 8,739

Interest Expense and Other (Tab

Interest Expense and Other (Tables)	12 Months Ended
Interest Expense and Other (Tables)	Dec. 31, 2022
Other Income and Expenses [Abstract]
Schedule of Interest Expense and Other	Interest expense and other for the years ended December 31, 2022 and 2021 consisted of the following (in thousands): Twelve months ended December 31, 2022 2021 Interest on term loan debt $ — $ 630 Interest on PPP loan — 11 Interest on 2020 convertible note — 700 Amortization of debt issuance costs — 725 2022 convertible note issuance costs 474 — Amortization of debt discount — 752 Amortization of premiums on marketable securities, net of accretion of discounts 778 456 Realized losses on redemptions of marketable securities 77 — Common stock purchase agreement transaction costs 29 1,583 Other 21 — Interest expense and other $ 1,379 $ 4,857

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2022
Equity [Abstract]
Schedule of Reverse Recapitalization	The following table reconciles the elements of the Business Combination to the consolidated statements of cash flows and the consolidated statements of changes in stockholders’ deficit for period ended December 31, 2021 (in thousands, except share data): Cash - CF III's trust and cash (net of redemption) $ 36,811 Cash - Private offering 220,000 Less: transaction costs and advisory fees paid (52,661) Net Business Combination and private offering $ 204,150 The number of shares of common stock issued immediately following the closing of the Business Combination were: CF III Class A common stock, outstanding prior to Business Combination 23,000,000 Less: redemption of CF III Class A common stock 19,355,365 Class A common stock of CF III 3,644,635 CF III founder shares 5,750,000 CF III Private Placement shares 500,000 CF III Shares issued in PIPE 22,000,000 Business Combination and PIPE shares 31,894,635 Legacy AEye shares 122,509,667 August 16, 2021 154,404,302 The number of Legacy AEye shares was determined as follows: AEye shares AEye shares, effected for Exchange Ratio Balance at December 31, 2019 11,283,838 41,984,908 Recapitalization applied to Convertible preferred stock outstanding at December 31, 2019 16,383,725 60,960,574 Exercise of common stock options - 2020 504,524 1,877,233 Repurchase of common stock - 2020 (950,352) (3,536,070) Exercise of common stock options - 2021 (pre-Closing) 54,859 204,119 Conversion of Convertible Notes and Accrued Interest – 2021 5,584,308 20,778,097 Exercise of common stock and Series A preferred stock warrants - 2021 64,719 240,806 Total 122,509,667 August 16, 2021 (Closing) Preferred stock shares Exchange ratio Common stock shares Series A Convertible preferred stock (pre-combination) 9,226,734 3.7208 34,330,838 Series B Convertible preferred stock (pre-combination) 7,156,991 3.7208 26,629,736 Total 16,383,725 60,960,574

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
Accumulated Other Comprehensive Loss (Tables)	Dec. 31, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The changes in accumulated other comprehensive loss by component for the twelve months ended December 31, 2022 and 2021 are as follows (in thousands): Unrealized gains (losses) on available-for-sale securities Change in fair value due to instrument-specific credit risk Total Balance at December 31, 2020 $ — $ — $ — Other comprehensive loss, net of tax (391) — (391) Balance at December 31, 2021 (391) — (391) Other comprehensive loss before reclassifications, net of tax (940) (25) (965) Amounts reclassified from accumulated other comprehensive loss, net of tax 77 — 77 Net other comprehensive loss (863) (25) (888) Balance at December 31, 2022 $ (1,254) $ (25) $ (1,279)

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
Net Loss per Share (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share	The following table sets forth the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data): Twelve months ended December 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (98,714) $ (65,011) Denominator: Weighted average common shares outstanding- Basic 157,368,707 109,055,894 Dilutive effect of potential common shares — — Weighted average common shares outstanding- Diluted 157,368,707 109,055,894 Net loss per share attributable to common stockholders - Basic and Diluted $ (0.63) $ (0.60)
Schedule of Antidilutive Common Share Equivalents	The following table sets forth the anti-dilutive common share equivalents for the periods listed: Twelve months ended December 31, 2022 2021 Warrants 9,583,322 7,833,332 Common stock options issued and outstanding 25,393,540 29,238,432 Unvested restricted stock units 12,771,096 7,434,743 Conversion of convertible notes 16,293,602 — ESPP 2,000,000 — Total 66,041,560 44,506,507

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity related to the Plans as of December 31, 2022 is as follows: Outstanding Stock Options Weighted Average Exercise Price Weighted Average Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2021 29,238,432 $ 0.48 7.35 $ 127,345 Granted — — Exercised (3,219,957) 0.36 Forfeited (569,123) 0.60 Expired (55,812) 0.17 Repurchased — — Balance at December 31, 2022 25,393,540 $ 0.49 6.45 $ 2,277 Vested and expected to vest as of December 31, 2022 25,393,540 $ 0.49 6.45 $ 2,277 Vested and exercisable as of December 31, 2022 20,356,221 $ 0.47 6.14 $ 2,277
Schedule of RSU Activity	The following table summarizes the RSU award activity under the Plans: Shares Weighted Average Grant date Fair Value per Share Unvested at December 31, 2021 7,434,743 $ 5.80 Granted 11,719,867 3.49 Forfeited (2,475,483) 4.37 Vested (3,908,031) 4.99 Unvested at December 31, 2022 12,771,096 $ 4.00
Schedule of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense recorded in each component of operating expenses in the Company’s consolidated statements of operations and comprehensive loss for the year ended December 31, 2022 and 2021 (in thousands): Twelve months ended December 31, 2022 2021 Research and development $ 7,201 $ 2,175 Sales and marketing 4,696 1,381 General and administrative 11,931 6,462 Cost of revenue 131 — Total stock-based compensation $ 23,959 $ 10,018
Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	The following table summarizes the range of valuation assumptions used in estimated the fair value of the ESPP during the period: Year Ended December 31, 2022 Expected term (years) 0.5 - 2 Expected volatility 94.8% - 105.3% Risk-free interest rate 4.5% - 4.8% Dividend yield — %

Revenue (Tables)

Revenue (Tables)	12 Months Ended
Revenue (Tables)	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Total revenue based on the disaggregation criteria described above are as follows (in thousands): Twelve months ended December 31, 2022 2021 Revenue by primary geographical market: United States $ 2,471 $ 2,215 Germany 65 536 Europe 855 111 Asia 256 145 Total $ 3,647 $ 3,007 Revenue by timing of recognition: Recognized at a point in time $ 1,982 $ 2,991 Recognized over time 1,665 16 Total $ 3,647 $ 3,007
Schedule of Contract Liabilities	Contract liabilities consisted of the following as of December 31, 2022 and 2021 (in thousands): As of December 31, 2022 2021 Contract liabilities, current $ 987 $ 2,287 Contract liabilities, noncurrent — 631 Total $ 987 $ 2,918 The following table shows the significant changes in contract liabilities balance as of December 31, 2022 and 2021 (in thousands): Twelve months ended December 31, 2022 2021 Beginning balance $ 2,918 $ 660 Revenue recognized that was included in the contract liabilities beginning balance (1,931) (570) Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period — 2,828 Ending balance $ 987 $ 2,918

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Federal Statutory Rate to Effective Tax Rate	The following table presents a reconciliation of the federal statutory rate of 21.0% to our effective tax rate for the periods presented: Twelve months ended December 31, 2022 2021 U.S. federal tax benefit at statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 0.0 % 11.8 % Non-deductible expenses and other (1.0) % (0.3) % Stock-based compensation (2.3) % (1.1) % Research and development credits 3.5 % 1.2 % Transaction Cost 0.0 % 3.9 % Foreign rate differential (4.1) % (3.1) % Change in valuation allowance, net (17.2) % (33.4) % Effective tax rate (0.1) % 0.0 %
Schedule of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2022 and December 31, 2021 are presented below: As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 49,669 $ 41,856 Research and development credit carryforward 7,967 4,545 Stock-based compensation 1,048 1,040 Property and equipment 234 178 Operating lease liabilities 4,435 — Section 174 R&D capitalization 9,053 — Other accruals 630 734 Gross deferred tax assets 73,036 48,353 Valuation allowance (68,868) (48,353) Deferred tax assets net of valuation allowance 4,168 — Deferred tax liabilities: Right-of-use assets (4,168) — Gross deferred tax liabilities (4,168) — Total deferred tax assets (liabilities)—net $ — $ —
Schedule of Reconciliation of Unrecognized Tax Benefits	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits: Twelve months ended December 31, 2022 2021 Unrecognized tax benefits as of the beginning of the year $ 1,681 $ 1,210 Increases related to prior year tax provisions 182 40 Increase related to current year tax provisions 959 431 Unrecognized tax benefits as of the end of the year $ 2,822 $ 1,681

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)	Jan. 01, 2022 USD ($)
Organization and Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents and marketable securities	$ 94,200,000
Number of reportable segments \| segment	1
Number of operating segments \| segment	1
Property and equipment, net	$ 7,665,000	$ 5,129,000
Restricted cash	2,150,000	2,150,000
Accounts receivable write-offs	0	0
Allowance for doubtful accounts	0	0
Inventory allowance	833,000	1,122,000
Impairment charges	$ 0	0
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities
Term of standard product warranties	1 year
Contract assets	$ 0
Interest and penalties recorded related to unrecognized tax benefits	0	0
Operating lease right-of-use assets	15,502,000	0
Present value of lease liabilities	$ 19,136,000
Deferred rent credit		$ (3,637,000)
Cumulative Effect, Period of Adoption, Adjustment
Organization and Summary of Significant Accounting Policies [Line Items]
Deferred rent credit			$ 3,032,000
Minimum
Organization and Summary of Significant Accounting Policies [Line Items]
Useful life of property and equipment	2 years
Minimum \| Cumulative Effect, Period of Adoption, Adjustment \| Pro Forma
Organization and Summary of Significant Accounting Policies [Line Items]
Operating lease right-of-use assets	$ 16,284,000
Maximum
Organization and Summary of Significant Accounting Policies [Line Items]
Useful life of property and equipment	7 years
Maximum \| Cumulative Effect, Period of Adoption, Adjustment \| Pro Forma
Organization and Summary of Significant Accounting Policies [Line Items]
Present value of lease liabilities	$ 19,921,000
Accounts Receivable \| Customer Concentration Risk \| Customer One
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%	10%
Accounts Receivable \| Customer Concentration Risk \| Customer Two
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%
Accounts Receivable \| Customer Concentration Risk \| Customer Three
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%
Accounts Receivable \| Customer Concentration Risk \| Customer Four
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%
Accounts Payable \| Supplier Concentration Risk \| Vendor One
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%	10%
Accounts Payable \| Supplier Concentration Risk \| Vendor Two
Organization and Summary of Significant Accounting Policies [Line Items]
Concentration risk percentage (more than)	10%	10%
Letter of Credit
Organization and Summary of Significant Accounting Policies [Line Items]
Maximum capacity	$ 2,150,000
United States
Organization and Summary of Significant Accounting Policies [Line Items]
Property and equipment, net	7,207,000
Europe
Organization and Summary of Significant Accounting Policies [Line Items]
Property and equipment, net	108,000
Asia
Organization and Summary of Significant Accounting Policies [Line Items]
Property and equipment, net	$ 350,000

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Schedule of Revenue from Major Customers Representing 10% or More of Total Revenue (Details) - Revenue - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A
Concentration Risk [Line Items]
Concentration risk percentage	51%	55%
Customer B
Concentration Risk [Line Items]
Concentration risk percentage	13%
Customer C
Concentration Risk [Line Items]
Concentration risk percentage	10%

Recapitalization - Narrative (D

Recapitalization - Narrative (Details) $ / shares in Units, $ in Thousands				7 Months Ended	12 Months Ended
	Aug. 16, 2021 USD ($) $ / shares shares	Aug. 15, 2021 $ / shares shares	Aug. 12, 2021 USD ($) $ / shares shares	Aug. 15, 2021 $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 shares	Dec. 31, 2019 shares
Schedule Of Reverse Recapitalization [Line Items]
Common stock and preferred stock — shares authorized (in shares)	301,000,000
Common stock — shares authorized (in shares)	300,000,000				300,000,000	300,000,000
Common stock — par value (in dollars per share) \| $ / shares	$ 0.0001				$ 0.0001	$ 0.0001
Preferred stock — shares authorized (in shares)	1,000,000				1,000,000	1,000,000
Preferred stock — par value (in dollars per share) \| $ / shares	$ 0.0001				$ 0.0001	$ 0.0001
Exchange ratio	3.7208
Conversion of convertible notes and accrued interest (in shares)					1,029,699
Convertible preferred stock conversion ratio		1		1
Warrant exercise price (in dollars per share) \| $ / shares	$ 11.50				$ 11.50
Warrant period exercisable	30 days
Warrant expiration period	5 years
Transaction costs recorded to additional paid-in capital \| $	$ 52,661					$ 52,661
Transaction costs expensed \| $	2,198
Gross proceeds from Business Combination \| $	$ 256,811
PIPE Subscription, All Investors
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	22,000,000
Purchase price (in dollars per share) \| $ / shares	$ 10
Aggregate purchase price \| $	$ 220,000
PIPE Subscription, Defaulted Investor
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	500,000
Purchase price (in dollars per share) \| $ / shares	$ 10
Aggregate purchase price \| $	$ 5,000
AEye Technologies \| Common Stock Warrants
Schedule Of Reverse Recapitalization [Line Items]
Outstanding warrants exercised (in shares)		61,612		61,612
Net settlement of common stock and Series A preferred stock warrants (in shares)		57,770
Warrant exercise price (in dollars per share) \| $ / shares		$ 37.21		$ 37.21
AEye Technologies \| Series A Preferred Warrants
Schedule Of Reverse Recapitalization [Line Items]
Outstanding warrants exercised (in shares)		7,353		7,353
Net settlement of common stock and Series A preferred stock warrants (in shares)		6,949
Warrant exercise price (in dollars per share) \| $ / shares		$ 37.21		$ 37.21
CF III
Schedule Of Reverse Recapitalization [Line Items]
Redemption of shares (in shares)			19,355,365
Value of redemption of shares \| $			$ 195,498
Redemption price per share (in dollars per share) \| $ / shares			$ 10.10
Common Stock
Schedule Of Reverse Recapitalization [Line Items]
Conversion of convertible notes and accrued interest (in shares)	20,778,097			20,778,097		20,778,097
Net settlement of common stock and Series A preferred stock warrants (in shares)				240,806		240,806
Redemption of shares (in shares)							3,536,070
Common Stock \| AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Conversion of convertible notes and accrued interest (in shares)		5,584,308		5,584,308
Shares outstanding (in shares)								11,283,838
Net settlement of common stock and Series A preferred stock warrants (in shares)				64,719
Redemption of shares (in shares)							950,352
Preferred Stock \| AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)								16,383,725
Preferred Stock \| AEye Technologies \| Retroactive application of recapitalization
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)		16,383,725		16,383,725

Recapitalization - Reconciliati

Recapitalization - Reconciliation of Elements of the Business Combination to the Financial Statements (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 16, 2021	Dec. 31, 2021
Reverse Recapitalization [Abstract]
Cash - CF III's trust and cash (net of redemption)		$ 36,811
Cash - Private offering		220,000
Less: transaction costs and advisory fees paid	$ (52,661)	(52,661)
Net Business Combination and private offering		$ 204,150

Recapitalization - Shares Issue

Recapitalization - Shares Issued Immediately Following the Consummation of the Business Combination (Details) - shares	Aug. 16, 2021	Aug. 12, 2021	Dec. 31, 2022	Dec. 31, 2021	Aug. 15, 2021
Schedule Of Reverse Recapitalization [Line Items]
Class A common stock, outstanding (in shares)	154,404,302		163,099,124	155,137,237
Legacy AEye shares (in shares)	122,509,667
CF III
Schedule Of Reverse Recapitalization [Line Items]
Class A common stock, outstanding (in shares)					23,000,000
Less: redemption of CF III Class A common stock (in shares)		19,355,365
AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Business Combination and PIPE shares (in shares)	31,894,635
Legacy AEye shares (in shares)	122,509,667
AEye Technologies \| Common Shareholders
Schedule Of Reverse Recapitalization [Line Items]
Business Combination and PIPE shares (in shares)	3,644,635
AEye Technologies \| Founder shares
Schedule Of Reverse Recapitalization [Line Items]
Business Combination and PIPE shares (in shares)	5,750,000
AEye Technologies \| Private Placement
Schedule Of Reverse Recapitalization [Line Items]
Business Combination and PIPE shares (in shares)	500,000
AEye Technologies \| Shares issued in PIPE
Schedule Of Reverse Recapitalization [Line Items]
Business Combination and PIPE shares (in shares)	22,000,000

Recapitalization - Calculation

Recapitalization - Calculation of Legacy AEye Shares (Details) - shares			7 Months Ended	12 Months Ended
	Aug. 16, 2021	Aug. 15, 2021	Aug. 15, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Reverse Recapitalization [Line Items]
Exercise of common stock options (in shares)				3,219,957
Conversion of convertible notes and accrued interest (in shares)				1,029,699
Legacy AEye shares (in shares)	122,509,667
AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Legacy AEye shares (in shares)	122,509,667
Common Stock
Schedule Of Reverse Recapitalization [Line Items]
Exercise of common stock options (in shares)			204,119	3,219,957	312,037	1,877,233
Repurchase of common stock (in shares)						(3,536,070)
Conversion of convertible notes and accrued interest (in shares)	20,778,097		20,778,097		20,778,097
Exercise of common stock and Series A preferred stock warrants (in shares)			240,806		240,806
Common Stock \| Reverse Recapitalization, Converted Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)							41,984,908
Common Stock \| AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)							11,283,838
Exercise of common stock options (in shares)			54,859			504,524
Repurchase of common stock (in shares)						(950,352)
Conversion of convertible notes and accrued interest (in shares)		5,584,308	5,584,308
Exercise of common stock and Series A preferred stock warrants (in shares)			64,719
Preferred Stock \| Reverse Recapitalization, Converted Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)							60,960,574
Preferred Stock \| AEye Technologies
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)							16,383,725

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents, adjusted cost	$ 19,064	$ 14,183
Recurring
Assets
Cash and cash equivalents and marketable securities, adjusted cost	90,642	155,078
Marketable securities, unrealized losses	(1,254)	(391)
Total financial assets, fair value	89,388	154,687
Liabilities
Total financial liabilities	9,200	155
Recurring \| Cash and Cash Equivalent
Assets
Total financial assets, fair value	14,253	4,863
Recurring \| Marketable Securities
Assets
Total financial assets, fair value	75,135	149,824
Recurring \| Level 1 \| Money market funds
Assets
Cash and cash equivalents, adjusted cost	14,253	4,863
Cash and cash equivalents, fair value	14,253	4,863
Recurring \| Level 1 \| Money market funds \| Cash and Cash Equivalent
Assets
Cash and cash equivalents, fair value	14,253	4,863
Recurring \| Level 2 \| Private Placement Warrants
Liabilities
Warrant liability	7	155
Recurring \| Level 2 \| Asset-backed securities
Assets
Marketable securities, adjusted cost	3,507	26,491
Marketable securities, unrealized losses	(119)	(68)
Marketable securities, fair value	3,388	26,423
Recurring \| Level 2 \| Asset-backed securities \| Marketable Securities
Assets
Marketable securities, fair value	3,388	26,423
Recurring \| Level 2 \| Corporate bonds
Assets
Marketable securities, adjusted cost	22,139	48,643
Marketable securities, unrealized losses	(240)	(150)
Marketable securities, fair value	21,899	48,493
Recurring \| Level 2 \| Corporate bonds \| Marketable Securities
Assets
Marketable securities, fair value	21,899	48,493
Recurring \| Level 2 \| Commercial paper
Assets
Marketable securities, adjusted cost	20,760	45,145
Marketable securities, unrealized losses	0	0
Marketable securities, fair value	20,760	45,145
Recurring \| Level 2 \| Commercial paper \| Marketable Securities
Assets
Marketable securities, fair value	20,760	45,145
Recurring \| Level 2 \| U.S. Government securities
Assets
Marketable securities, adjusted cost	29,983	29,936
Marketable securities, unrealized losses	(895)	(173)
Marketable securities, fair value	29,088	29,763
Recurring \| Level 2 \| U.S. Government securities \| Marketable Securities
Assets
Marketable securities, fair value	29,088	$ 29,763
Recurring \| Level 3
Liabilities
Convertible notes	8,594
Recurring \| Level 3 \| Warrants
Liabilities
Derivative warrant liability	$ 119

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	Dec. 31, 2022	Sep. 15, 2022
Debt Instrument [Line Items]
Warrant, term of contract	4 years
2022 Notes, First Closing \| 2022 Convertible Note
Debt Instrument [Line Items]
Loan amount		$ 10,500,000

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Level 3 Financial Instruments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Change in fair value due to instrument-specific credit risk, net of tax
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0
Additions	10,000
Payments or conversions	(1,474)
Change in fair value included in other income (expense)	162
Change in fair value due to instrument specific credit risk included in other comprehensive income	25
Ending balance	8,713
2022 Convertible Note
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
Additions	9,512
Payments or conversions	(1,474)
Change in fair value included in other income (expense)	531
Change in fair value due to instrument specific credit risk included in other comprehensive income	25
Ending balance	8,594
Derivative Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
Additions	488
Payments or conversions	0
Change in fair value included in other income (expense)	(369)
Change in fair value due to instrument specific credit risk included in other comprehensive income	0
Ending balance	$ 119

Fair Value Measurements - Key I

Fair Value Measurements - Key Inputs into Valuation Models (Details) - Recurring - Level 3	Dec. 31, 2022 $ / shares
Binomial Lattice Model \| Remaining term (years) \| 2022 Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	1.2
Binomial Lattice Model \| Expected volatility \| 2022 Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.904
Binomial Lattice Model \| Risk-free interest rate \| 2022 Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.046
Binomial Lattice Model \| Dividend yield \| 2022 Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0
Binomial Lattice Model \| Estimated credit spread \| 2022 Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.377
Monte Carlo Simulation Model \| Remaining term (years) \| Derivative Warrant Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	3.7
Monte Carlo Simulation Model \| Expected volatility \| Derivative Warrant Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0.904
Monte Carlo Simulation Model \| Risk-free interest rate \| Derivative Warrant Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0.041
Monte Carlo Simulation Model \| Dividend yield \| Derivative Warrant Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0
Monte Carlo Simulation Model \| Exercise price \| Derivative Warrant Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	3.50

Cash, Cash Equivalents, and R_3

Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 19,064	$ 14,183
Restricted cash	2,150	2,150
Total cash, cash equivalents, and restricted cash	$ 21,214	$ 16,333	$ 16,498

Inventories - Components of Inv

Inventories - Components of Inventory, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 2,022	$ 1,544
Work in-process	2,484	2,447
Finished goods	47	94
Inventories, net	$ 4,553	$ 4,085

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Non-current inventory	$ 1,491	$ 0

Prepaid and Other Current Ass_3

Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 4,203	$ 3,980
Demonstration units	281	224
Advances to suppliers	984	745
Other	713	102
Prepaid and other current assets	$ 6,181	$ 5,051

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Rental expense	$ 1,876
Deferred rent liabilities	$ 3,637
Minimum
Lessee, Lease, Description [Line Items]
Lease extension term		2 years
Maximum
Lessee, Lease, Description [Line Items]
Lease extension term		5 years

Leases - Operating Lease Expens

Leases - Operating Lease Expenses (Details) $ in Thousands	12 Months Ended
Leases - Operating Lease Expenses (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
Operating lease cost	$ 2,382
Variable lease cost	241
Total operating lease cost	$ 2,623

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Leases [Abstract]
Cash paid for operating leases included in operating cash flows	$ (1,341)

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 15,502	$ 0
Operating lease liabilities:
Operating lease liabilities - current	2,455	0
Operating lease liabilities, noncurrent	16,681	$ 0
Total operating lease liabilities	$ 19,136
Weighted average remaining lease term (in years)	9 years 3 months 3 days
Weighted average discount rate	5.35%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 2,516
2024	2,570
2025	2,583
2026	2,660
2027	2,701
Thereafter	11,116
Total lease payments	24,146
Less amount to discount to present value	(5,010)
Present value of lease liabilities	$ 19,136

Leases - Future Minimum Payment

Leases - Future Minimum Payments Under Noncancellable Operating Leases under ASC 840 (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 2,393
2023	2,341
2024	2,412
2025	2,484
2026 and after	2,340
Total minimum lease payments	$ 11,970

Property and Equipment, Net - C

Property and Equipment, Net - Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 10,688	$ 7,333
Less accumulated depreciation and amortization	(3,023)	(2,204)
Property and equipment, net	7,665	5,129
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,528	1,444
Computers, software and related equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	432	268
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	651	341
Vehicles
Property, Plant and Equipment [Line Items]
Total property and equipment	846	342
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	4,830	4,725
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 1,401	$ 213

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 1,422	$ 1,014
Property, plant and equipment, disposals	$ 604	$ 0

Other Noncurrent Assets (Detail

Other Noncurrent Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Non-current inventory	$ 1,491	$ 0
Long-term prepaid expenses	901	1,376
Security deposits	81	133
Total other noncurrent assets	$ 2,473	$ 1,509

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued purchases and other	$ 4,092	$ 1,947
Operating lease liabilities - current	2,455	0
Accrued bonuses	1,022	3,408
Accrued payroll	1,148	957
Accrued payroll taxes	480	275
Warranty reserve	526	1,547
Income tax payable	41	0
Deferred rent - current	0	605
Accrued expenses and other current liabilities	$ 9,764	$ 8,739

Borrowings (Details)

Borrowings (Details) - USD ($)						12 Months Ended
Borrowings (Details) - USD ($)	Sep. 07, 2021	Aug. 20, 2021	Jun. 19, 2021	May 13, 2021	Mar. 18, 2021	Dec. 31, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Gain on PPP loan forgiveness						$ 0	$ 2,297,000
Borrowing amount outstanding						$ 0	$ 0
Term Loan Debt \| Secured Debt
Line of Credit Facility [Line Items]
Principal payments on bank loans	$ 2,333,000
Paycheck Protection Program, CARES Act \| Loans Payable \| Principal
Line of Credit Facility [Line Items]
Gain on PPP loan forgiveness			$ 2,270,000
Paycheck Protection Program, CARES Act \| Loans Payable \| Interest
Line of Credit Facility [Line Items]
Gain on PPP loan forgiveness			$ 27,000
Financing Facility \| Silicon Valley Bank Financing Facility
Line of Credit Facility [Line Items]
Maximum capacity					$ 10,000,000
Interest rate					8%
Repayments for financing facility, including interest		$ 10,540,000
Financing Facility \| Silicon Valley Bank Financing Facility, First Advance
Line of Credit Facility [Line Items]
Maximum capacity					$ 4,000,000
Proceeds from bank loan					4,000,000
Financing Facility \| Silicon Valley Bank Financing Facility, Second Advance
Line of Credit Facility [Line Items]
Maximum capacity					$ 6,000,000
Proceeds from bank loan				$ 6,000,000

Convertible Notes - Narrative (

Convertible Notes - Narrative (Details)						7 Months Ended	12 Months Ended
Convertible Notes - Narrative (Details)	Dec. 15, 2022 USD ($) d $ / shares	Dec. 14, 2022 d $ / shares	Sep. 15, 2022 USD ($) redemptionAmount d $ / shares	Sep. 14, 2022 USD ($) issuance	Aug. 16, 2021 USD ($) shares	Aug. 15, 2021 shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Feb. 26, 2020 USD ($)
Debt Instrument [Line Items]
Convertible notes							$ 8,594,000	$ 0
Conversions of convertible note into common stock (in shares) \| shares							1,029,699
Convertible note issuance costs							$ 474,000	$ 0
2022 Convertible Note
Debt Instrument [Line Items]
Maximum beneficial ownership percentage allowed if converted			9.99%
Common Stock
Debt Instrument [Line Items]
Conversions of convertible note into common stock (in shares) \| shares					20,778,097	20,778,097		20,778,097
2020 Notes \| 2022 Convertible Note
Debt Instrument [Line Items]
Maximum amount of convertible equity instruments issuable									$ 40,000,000
Interest rate									3%
Convertible notes					$ 38,045,000		0	$ 0
Debt conversion multiplier percentage									90%
Fair value of embedded derivative liability							0	$ 0		$ 1,520,000
2022 Notes
Debt Instrument [Line Items]
Number of issuances allowed \| issuance				2
Proceeds receivable from convertible debt				$ 20,000,000
Number of monthly redemption amounts that can be accelerated in any calendar month \| redemptionAmount			4
Capital raise threshold amount			$ 5,000,000
Percentage required to be used to redeem debt			30%
Principal and unpaid interest multiplier			105%
Make-whole amount multiplier			100%
Convertible notes, fair value			$ 9,512,000				8,594,000
Warrant, fair value disclosure			$ 488,000
2022 Notes \| 2022 Convertible Note
Debt Instrument [Line Items]
Interest rate			5%
Discount on issuance, percentage			4.76%
Minimum weighted average price (in dollars per share) \| $ / shares	$ 0.33
Minimum average daily trading volume	$ 500,000,000
Trading days prior to the installment notice date \| d	20
Trading day prior to the installment date \| d	6
Conversion price (in dollars per share) \| $ / shares		$ 2.50	$ 0.30
Threshold percentage of stock price trigger		95%	95%
Threshold consecutive trading days \| d		5
Monthly redemption premium, percentage		5%
Acceleration payment monthly limit			$ 2,800,000
Convertible note issuance costs			474,000
Convertible notes outstanding							$ 9,200,000
2022 Notes, Each Closing
Debt Instrument [Line Items]
Proceeds receivable from convertible debt				10,000,000
2022 Notes, Each Closing \| 2022 Convertible Note
Debt Instrument [Line Items]
Loan amount				$ 10,500,000
2022 Notes, First Closing
Debt Instrument [Line Items]
Proceeds from the issuance of convertible notes			10,000,000
2022 Notes, First Closing \| 2022 Convertible Note
Debt Instrument [Line Items]
Loan amount			$ 10,500,000
2022 Notes, Second Closing
Debt Instrument [Line Items]
Trading days after agreement for issuance \| d			90

Interest Expense and Other (Det

Interest Expense and Other (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 0	$ 725
Convertible note issuance costs	474	0
Amortization of debt discount	0	752
Amortization of premiums on marketable securities, net of accretion of discounts	778	456
Realized loss on redemption of marketable securities	77	0
Common stock purchase agreement transaction costs	29	1,583
Other	21	0
Interest expense and other	1,379	4,857
Term Loan Debt
Debt Instrument [Line Items]
Interest	0	630
Paycheck Protection Program, CARES Act
Debt Instrument [Line Items]
Interest	0	11
2020 Convertible Note
Debt Instrument [Line Items]
Interest	$ 0	$ 700

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details)		12 Months Ended
Stockholders' Equity - Narrative (Details)	Dec. 08, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) vote $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Sep. 15, 2022 $ / shares shares	May 06, 2022 shares	Aug. 16, 2021 $ / shares shares
Class of Warrant or Right [Line Items]
Common stock — shares authorized (in shares)		300,000,000	300,000,000			300,000,000
Common stock — par value (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001			$ 0.0001
Common stock — shares issued (in shares)		163,099,124	155,137,237
Common stock — shares outstanding (in shares)		163,099,124	155,137,237			154,404,302
Number of votes \| vote		1
Exchange ratio						3.7208
Number of shares of common stock entitled to purchase for each warrant (in shares)		1
Warrant exercise price (in dollars per share) \| $ / shares		$ 11.50				$ 11.50
Noncash common stock purchase agreement costs \| $		$ 29,000	$ 1,583,000
Private Placement Warrants
Class of Warrant or Right [Line Items]
Outstanding warrants exercised (in shares)		166,666
Public Warrants
Class of Warrant or Right [Line Items]
Outstanding warrants exercised (in shares)		7,666,656
Convertible Note Warrants
Class of Warrant or Right [Line Items]
Outstanding warrants exercised (in shares)				1,750,000
Warrant exercise price (in dollars per share) \| $ / shares				$ 3.50
Warrants and Rights Outstanding, Term				4 years
Contingent Warrants
Class of Warrant or Right [Line Items]
Outstanding warrants exercised (in shares)		1,750,000
Warrant exercise price (in dollars per share) \| $ / shares		$ 3.50
Warrants and Rights Outstanding, Term		4 years
S-1 Registration \| Tumim Stone Capital
Class of Warrant or Right [Line Items]
Sale of Stock, Number of Shares Authorized to be Issued					30,865,419
Tumim Stone Capital
Class of Warrant or Right [Line Items]
Commitment shares for Common Stock Purchase Agreement (in shares)	302,634
Noncash common stock purchase agreement costs \| $		$ 1,583,000
Derivative asset \| $	$ 0
Tumim Stone Capital \| Private Placement
Class of Warrant or Right [Line Items]
Maximum common stock value \| $	$ 125,000,000
Exchange cap, percentage of shares of common stock outstanding immediately prior to execution of the agreement	19.99%
Exchange cap exception, minimum price per share (in dollars per share) \| $ / shares	$ 4.9485
Term of agreement	36 months
Maximum percentage ownership after the transaction	9.99%
Price per share multiplier	0.9615
Maximum number of shares issued per day calculation, amount divided by closing sale price \| $	$ 20,000,000
Maximum number of shares issued per day calculation, average daily common stock trading volume multiplier	0.15
Maximum number of shares issued per day calculation, average daily common stock trading volume, trading days preceding sale date	3 days
Shares issued in transaction (in shares)		1,145,000
Aggregate purchase price \| $		$ 2,891,000

Stockholders' Equity - Outstand

Stockholders' Equity - Outstanding Preferred Shares Converted (Details)	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Aug. 16, 2021 shares	Aug. 15, 2021 shares
Conversion of Stock [Line Items]
Preferred stock — shares outstanding (in shares)	0	0		16,383,725
Exchange ratio			3.7208
Common stock — shares outstanding (in shares)	163,099,124	155,137,237	154,404,302
Reverse Recapitalization, Converted Shares
Conversion of Stock [Line Items]
Common stock — shares outstanding (in shares)			60,960,574
Series A Convertible Preferred Stock
Conversion of Stock [Line Items]
Preferred stock — shares outstanding (in shares)				9,226,734
Series A Convertible Preferred Stock \| Reverse Recapitalization, Converted Shares
Conversion of Stock [Line Items]
Common stock — shares outstanding (in shares)			34,330,838
Series B Convertible Preferred Stock
Conversion of Stock [Line Items]
Preferred stock — shares outstanding (in shares)				7,156,991
Series B Convertible Preferred Stock \| Reverse Recapitalization, Converted Shares
Conversion of Stock [Line Items]
Common stock — shares outstanding (in shares)			26,629,736

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 168,767	$ (18,225)
Other comprehensive loss before reclassifications, net of tax	(965)
Amounts reclassified from accumulated other comprehensive loss, net of tax	77	0
Other comprehensive loss, net of tax	(888)	(391)
Ending balance	93,970	168,767
Unrealized gains (losses) on available-for-sale securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(391)	0
Other comprehensive loss before reclassifications, net of tax	(940)
Amounts reclassified from accumulated other comprehensive loss, net of tax	77
Other comprehensive loss, net of tax	(863)	(391)
Ending balance	(1,254)	(391)
Change in fair value due to instrument-specific credit risk
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0	0
Other comprehensive loss before reclassifications, net of tax	(25)
Amounts reclassified from accumulated other comprehensive loss, net of tax	0
Other comprehensive loss, net of tax	(25)	0
Ending balance	(25)	0
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(391)	0
Other comprehensive loss, net of tax	(888)
Ending balance	$ (1,279)	$ (391)

Net Loss per Share - Basic and

Net Loss per Share - Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss attributable to common stockholders	$ (98,714)	$ (65,011)
Denominator:
Weighted average common shares outstanding - Basic (in shares)	157,368,707	109,055,894
Dilutive effect of potential common shares (in shares)	0	0
Weighted average common shares outstanding - Diluted (in shares)	157,368,707	109,055,894
Net loss per share attributable to common stockholders - (basic) (in dollars per share)	$ (0.63)	$ (0.60)
Net loss per share attributable to common stockholders - (diluted) (in dollars per share)	$ (0.63)	$ (0.60)

Net Loss per Share - Anti-Dilut

Net Loss per Share - Anti-Dilutive Common Share Equivalents (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	66,041,560	44,506,507
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	9,583,322	7,833,332
Common stock options issued and outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	25,393,540	29,238,432
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	12,771,096	7,434,743
Conversion of convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	16,293,602	0
ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	2,000,000	0

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details)			12 Months Ended			108 Months Ended
Stock-Based Compensation - Narrative (Details)	May 10, 2022 USD ($) purchasePeriod shares	Aug. 16, 2021 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 USD ($) plan shares	Dec. 31, 2021 USD ($) shares	Jan. 01, 2032
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| plan				4
Repurchase of stock options \| $				$ 0	$ 1,500,000
Options granted (in shares) \| shares				0	0
Unrecognized compensation expense for stock option grants \| $			$ 5,418,000	$ 5,418,000
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of stock options \| $		$ 1,500,000
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares) \| shares		15,440,430
Annual increase, percentage of outstanding stock maximum				5%
Additional share authorized (in shares) \| shares			7,743,413
2021 Plan \| Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase, percentage of outstanding stock maximum						3%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares) \| shares				11,719,867
Fair value of awards that vested \| $				$ 10,992,000
Unrecognized compensation expense, period for recognition				2 years 5 months 8 days
Unrecognized compensation expense for RSU's \| $			$ 47,007,000	$ 47,007,000
RSUs \| 2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares) \| shares				1,741,689
Vesting period				4 years
RSUs \| 2016 Plan \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				25%
RSUs \| 2016 Plan \| Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
RSUs \| 2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares) \| shares				17,891,938
RSUs \| 2021 Plan \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				1 year
Vesting percentage				25%
RSUs \| 2021 Plan \| Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
Common stock options issued and outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition				1 year 4 months 6 days
Common stock options issued and outstanding \| 2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
Expiration period				10 years
Options to be repurchased (in shares) \| shares		542,615
Common stock options issued and outstanding \| 2016 Plan \| Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				25%
Common stock options issued and outstanding \| 2016 Plan \| Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
Common stock options issued and outstanding \| 2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				10 years
Common stock options issued and outstanding \| 2014 Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares) \| shares	2,000,000
Annual increase, percentage of outstanding stock maximum	1%
Share-based compensation offering period	24 months
Number of purchase periods \| purchasePeriod	4
Purchase period duration	6 months
Share-based compensation arrangement minimum employee subscription rate	1%
Maximum contribution as a percentage of compensation	10%
Maximum contribution per purchase period \| $	$ 15,000
Maximum contribution per purchase year \| $	$ 25,000
Purchase price as a percentage of fair market value	85%
Stock issued during period, shares, employee stock purchase plans (in shares) \| shares				0
Amounts withheld for employee stock purchases \| $			188,000	$ 188,000
Unrecognized compensation expense, period for recognition				1 year 9 months 29 days
Unrecognized compensation expense for RSU's \| $			$ 1,152,000	$ 1,152,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Outstanding Stock Options
Beginning balance (in shares)	29,238,432
Granted (in shares)	0	0
Exercised (in shares)	(3,219,957)
Forfeited (in shares)	(569,123)
Expired (in shares)	(55,812)
Repurchased (in shares)	0
Ending balance (in shares)	25,393,540	29,238,432
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.48
Granted (in dollars per share)	0
Exercised (in dollars per share)	0.36
Forfeited (in dollars per share)	0.60
Expired (in dollars per share)	0.17
Repurchased (in dollars per share)	0
Ending balance (in dollars per share)	$ 0.49	$ 0.48
Stock options additional disclosures
Options outstanding, weighted average contractual life	6 years 5 months 12 days	7 years 4 months 6 days
Options outstanding, aggregate intrinsic value	$ 2,277	$ 127,345
Vested and expected to vest (in shares)	25,393,540
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.49
Vested and expected to vest, weighted average contractual life	6 years 5 months 12 days
Vested and expected to vest, aggregate intrinsic value	$ 2,277
Vested and exercisable (in shares)	20,356,221
Vested and exercisable, weighted average exercise price (in dollars per share)	$ 0.47
Vested and exercisable, weighted average contractual life	6 years 1 month 20 days
Vested and exercisable, aggregate intrinsic value	$ 2,277

Stock-Based Compensation - RSU

Stock-Based Compensation - RSU Activity (Details) - RSUs	12 Months Ended
Stock-Based Compensation - RSU Activity (Details) - RSUs	Dec. 31, 2022 $ / shares shares
Shares
Beginning balance (in shares) \| shares	7,434,743
Granted (in shares) \| shares	11,719,867
Forfeited (in shares) \| shares	(2,475,483)
Vested (in shares) \| shares	(3,908,031)
Ending balance (in shares) \| shares	12,771,096
Weighted Average Grant date Fair Value per Share
Beginning balance (in dollars per share) \| $ / shares	$ 5.80
Granted (in dollars per share) \| $ / shares	3.49
Forfeited (in dollars per share) \| $ / shares	4.37
Vested (in dollars per share) \| $ / shares	4.99
Ending balance (in dollars per share) \| $ / shares	$ 4

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 23,959	$ 10,018
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	7,201	2,175
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	4,696	1,381
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	11,931	6,462
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 131	$ 0

Stock-Based Compensation - ESPP

Stock-Based Compensation - ESPP Valuation Assumptions (Details) - ESPP	12 Months Ended
	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility rate, minimum	94.80%
Expected volatility rate, maximum	105.30%
Risk-free interest rate, minimum	4.50%
Risk-free interest rate, maximum	4.80%
Dividend yield	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	2 years

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 3,647	$ 3,007
Revenue recognized for performance obligation satisfied	1,904	2,003
Prototype sales
Disaggregation of Revenue [Line Items]
Revenue	$ 1,743	$ 1,004

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 3,647	$ 3,007
Recognized at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	1,982	2,991
Recognized over time
Disaggregation of Revenue [Line Items]
Total revenue	1,665	16
United States
Disaggregation of Revenue [Line Items]
Total revenue	2,471	2,215
Germany
Disaggregation of Revenue [Line Items]
Total revenue	65	536
Europe
Disaggregation of Revenue [Line Items]
Total revenue	855	111
Asia
Disaggregation of Revenue [Line Items]
Total revenue	$ 256	$ 145

Revenue - Contract Liabilities

Revenue - Contract Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract liabilities, current	$ 987	$ 2,287
Contract liabilities, noncurrent	0	631
Total	987	2,918
Contract with Customer, Liability [Roll Forward]
Beginning balance	2,918	660
Revenue recognized that was included in the contract liabilities beginning balance	(1,931)	(570)
Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period	0	2,828
Ending balance	$ 987	$ 2,918

Employee Benefit Plan - (Detail

Employee Benefit Plan - (Details) - Plan 401K - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Match percentage	100%
Percentage of employee earnings eligible for match	5%
Contributions to employee benefit plan	$ 1,177	$ 565
Defined Contribution Plan, Match, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Match percentage		100%
Percentage of employee earnings eligible for match		3%
Defined Contribution Plan, Match, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Match percentage		50%
Percentage of employee earnings eligible for match		2%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
Income Taxes - Narrative (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 58,000	$ 0
U.S. federal tax benefit at statutory rate	21%	21%
Valuation allowance	$ (68,868,000)	$ (48,353,000)
Undistributed earnings of foreign subsidiaries	111,000
Accrued interest and penalties related to uncertain tax positions	0	0
Federal
Operating Loss Carryforwards [Line Items]
Net operating losses available to reduce future taxable income	184,007,000	156,584,000
Net operating losses available to reduce future taxable income subject to expiration	12,256,000
Net operating losses available to reduce future taxable income not subject to expiration	171,751,000
Federal \| Research and development
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	6,193,000	3,373,000
State
Operating Loss Carryforwards [Line Items]
Provision for income taxes	9,000
Net operating losses available to reduce future taxable income	127,624,000	104,555,000
Net operating losses available to reduce future taxable income subject to expiration	5,033,000
State \| Research and development
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	4,597,000	$ 2,854,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 49,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
U.S. federal tax benefit at statutory rate	21%	21%
State income taxes, net of federal benefit	0%	11.80%
Non-deductible expenses and other	(1.00%)	(0.30%)
Stock-based compensation	(2.30%)	(1.10%)
Research and development credits	3.50%	1.20%
Transaction Cost	0%	3.90%
Foreign rate differential	(4.10%)	(3.10%)
Change in valuation allowance, net	(17.20%)	(33.40%)
Effective tax rate	(0.10%)	(0.00%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 49,669	$ 41,856
Research and development credit carryforward	7,967	4,545
Stock-based compensation	1,048	1,040
Property and equipment	234	178
Operating lease liabilities	4,435	0
Section 174 R&D capitalization	9,053	0
Other accruals	630	734
Gross deferred tax assets	73,036	48,353
Valuation allowance	(68,868)	(48,353)
Deferred tax assets net of valuation allowance	4,168	0
Deferred tax liabilities:
Right-of-use assets	(4,168)	0
Gross deferred tax liabilities	(4,168)	0
Total deferred tax assets (liabilities)—net	$ 0	$ 0

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits as of the beginning of the year	$ 1,681	$ 1,210
Increases related to prior year tax provisions	182	40
Increase related to current year tax provisions	959	431
Unrecognized tax benefits as of the end of the year	$ 2,822	$ 1,681

Related Parties - Narrative (De

Related Parties - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
RSUs
Related Party Transaction [Line Items]
Awards granted (in shares)	11,719,867
Sibling of President and CTO
Related Party Transaction [Line Items]
Cash compensation	$ 162	$ 136
Sibling of President and CTO \| RSUs
Related Party Transaction [Line Items]
Awards granted (in shares)	22,500	1,860

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Mar. 10, 2023	Dec. 31, 2022	Dec. 31, 2021	Aug. 16, 2021	Aug. 12, 2021	Aug. 11, 2021
Subsequent Event [Line Items]
Common stock — shares authorized (in shares)		300,000,000	300,000,000	300,000,000
Subsequent Event
Subsequent Event [Line Items]
Cash deposited at bank closed by California Department of Financial Protection and Innovation	$ 9,600
Subsequent Event \| Asset Pledged as Collateral
Subsequent Event [Line Items]
Cash deposited at bank closed by California Department of Financial Protection and Innovation	$ 2,150
Common Class A
Subsequent Event [Line Items]
Common stock — shares authorized (in shares)					300,000,000	200,000,000